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ABSTRACT
The spontaneous production of autoantibodies against tumour-derived proteins has been 
observed in the most, if not all cancer patients and they seem to be very attractive biomarkers 
for  the  diagnosis,  early  detection  and  prognosis  of  cancer  and  prediction  of  response  to 
immunotherapy. However, so far their clinical utility has been hampered by the low frequency 
of antibodies against each individual antigen, heterogeneity of the autoantibody repertoire and 
its  overlap  with that  in  the response to  tissue  damage by viral  infections  or  autoimmune 
diseases.  These  limitations  at  least  partially  could  be  overcome  by  exploiting  protein 
microarray technology that allows detecting the autoantibodies against thousands of antigens 
simultaneously using a microliter of serum and hence represent a valuable tool for exploring 
autoantibody profiles in human sera and defining autoantibody signatures with the diagnostic 
or prognostic relevance.
This  thesis  is  focused  on  the  development  of  technology  for  the  production  and 
processing of phage-displayed antigen microarrays and procedures for the data analysis, and 
their application for the exploration of autoantibody profiles in patients with gastric cancer 
(GC),  gastric  inflammatory  diseases  and  healthy  individuals,  and  assessment  of  humoral 
immune response against sperm-associated antigens.
At first, series of experiments were performed to select the most suitable slide surface 
chemistry, printing conditions and the optimal method for amplification of phages, and to 
optimise the serum and antibody dilutions, incubation times and method of pre-absorption of 
serum. After having established the reproducibility of the technique, we  applied it for the 
characterization of the humoral immune response against a heterogeneous group of proteins 
called sperm associated antigens (SPAG) that are commonly expressed in male germ cells, are 
capable to elicit immune response underlying infertility, and several of them recently have 
been shown to be expressed in cancers and proposed to be implicated in the development of 
cancer.  Cancer-associated  spontaneous  humoral  immune  response  was  detected  against 
SPAG1, SPAG6, SPAG8 and a novel testis-restricted splice variant SPAG17-A1 that allowed 
to classify them as novel CT antigens with potential relevance as immunotherapeutic targets 
and serological biomarkers.
Next,  1150-feature  antigen  microarrays  were  produced  by  printing  the  recombinant 
phage particles  from the  previously  established cancer  antigen  clone  collection  on  FAST 
slides  and applied  for  the  exploration  of  autoantibody profiles  in  melanoma patients  and 
healthy individuals. Initial data analysis demonstrated that the conventional methods, such as 
LOWESS or OLIN commonly used for the normalisation of DNA microarray data and the 
standard statistical methods such as t-tests and regression analysis as well  as  the artificial 
neural network-based approaches that are widely used for the analysis of gene expression 
data,  are  not suitable for the analysis  of antigen microarray data.  Next,  we evaluated the 
performance of support vector machines (SVM)-based approach with an improved kernel for 
the  generation  of  biomarker  model  for  discriminating  sera  from  melanoma  patients  and 
healthy controls. Although, the improvement of SVM with ranking-based topological kernel 
resulted  in  higher  classification  accuracy,  detailed  examination  of  the  biomarker  model 
showed that  it  is  based on the  detection of  small  but  consistent  differences  in  the signal 
intensities between the cases and controls. In our opinion, the biological significance of such 
differences is unclear and the development of clinically applicable biomarker assay based on 
such model would be technically extremely challenging. Therefore next, we endeavoured to 
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establish the procedures for the data normalisation, defining cutoffs that allow to discriminate 
between sero-positive and sero-negative cases, and ranking of antigens considering the signal 
intensity  and  the  frequency  of  reactivity.  This  approach  was  applied  for  the  survey  of 
autoantibody  profiles  in  patients  with  GC,  gastric  inflammatory  diseases  and  healthy 
individuals  and  resulted  in  the  identification  of  45-  autoantibody  signature  that  could 
discriminate between GC and healthy control sera with 74.5% accuracy (AUC of 0.79, 58% 
sensitivity  and 91% specificity),  GC and peptic  ulcer  with  73.0% accuracy,  and GC and 
gastritis with 63.5% accuracy. Moreover, it could detect early GC with equal sensitivity than 
advanced GC thus demonstrating its relevance for the early detection of GC. Interestingly, the 
autoantibody  production  did  not  correlate  with  histological  type,  H.  pylori status,  grade, 
localization  and  size  of  the  primary  tumor  while  it  appeared  to  be  associated  with  the 
metastatic disease. 
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INTRODUCTION
Despite  the  enormous  progress  in  the  understanding  of  pathogenesis  and molecular 
mechanisms of cancer, it remains a major health burden and the second leading cause of death 
worldwide. It accounts for ~7.6 million deaths (~13% of all deaths) per year worldwide and 
these figures are projected to continue to rise over 11 million in 2030 (1). Early detection and 
improved management of cancer patients are of paramount importance for the reduction of 
cancer  mortality.  Advancements  in  the  early  detection  can  be  achieved  by  implementing 
systematic screening programmes for an asymptomatic population or improving diagnostic 
approaches for specific target groups that would allow to start the treatment before the disease 
has spread beyond the original site and complete, curative resection is possible in the most 
cases of solid tumours. Hence, the identification of cancer biomarkers that could be detected 
in body fluids such as plasma, serum or urine and are suitable for the development of non-
invasive  or  minimally  invasive  tests  applicable  for  the  screening  programmes,  diagnosis, 
prognosis, monitoring or prediction of response to therapy would represent a significant step 
towards the reduction of morbidity and mortality caused by cancer. The discovery of prostate 
specific antigen (PSA) more than 30 years ago and its application in the screening, diagnosis 
and  monitoring  has  changed  the  way  how  prostate  cancer  is  diagnosed  and  treated  (2). 
However, despite the extensive interest it triggered, few other serum biomarkers have been 
introduced to the clinic since that and there are many difficult-to-diagnose cancers, such as 
gastric cancer, for which no reliable biomarker assays are currently available.
Humoral  immune response against  cancer-derived proteins has been detected by the 
classical or modified SEREX (serological identification of tumour antigens by recombinant 
expression cloning) approaches in all cancer types analyzed so far (3,4). Autoantibodies, due 
to their specificity and stability in sera, seem to be very attractive targets for the development 
of non-invasive serological tests for the diagnosis of cancer. In contrary to the currently know 
serum  biomarkers  such  as  PSA,  CEA or  CA19-9,  they  are  qualitative  not  quantitative 
biomarkers, which implies higher specificity. Furthermore, there is some evidence that the 
autoantibodies can be detected as early as several years before the clinical diagnosis (5) that 
demonstrates their value for the early detection. Moreover, even if they by themselves may 
have a minor role in the anti-tumour immune response, the autoantibody profile likely reflects 
the repertoire of activated CD4+ T cells, presumably, including both, the helper cells and the 
regulatory  T  cells.  Hence,  they  may  turn  out  to  be  valuable  biomarkers  for  monitoring 
patient’s response to immunotherapy. However, so far the development of autoantibody-based 
biomarker assays has been hampered by several factors: the frequency of antibodies against 
any  individual  TAA  is  generally  relatively  low,  typically  ranging  from  1  to  ~15%; 
autoantibody repertoire is heterogeneous and to some extent resemble the response to tissue 
damage by viral infections or autoimmune diseases, and  autoantibodies against a number of 
TAAs, such as CTAG1B, TP53, c-MYC etc.  are found in patients with different types of 
cancer  (6-9).  At  least  partially  these  limitations  could  be  overcome  by  applying  high-
throughput proteomic techniques to cancer serology that allows definition of a comprehensive 
set of antigens in each type of cancer and analysing the whole autoantibody repertoire in 
patients’ sera. In a previous study we applied T7 phage display-based SEREX technique to 
define the repertoire of antigens eliciting the autoantibody production in melanoma, breast, 
gastric and prostate cancer patients. This resulted in the identification of over 1300 different 
serum-reactive  phage  clones  encoding  known  cancer-testis  (CT)  antigens  such  as 
CTAG1B/NY-ESO1,  MAGEA,  SSX2,  DDX53,  HORMAD1  etc.,  a  number  of  non-CT 
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antigens that have been previously identified by applying conventional SEREX to various 
tumour  types  (ANXA11,  LIG1,  HDLBP,  SC65,  KTN1,  TPM3,  ZNF282,  EEF1A1  etc), 
several ribosomal proteins and heat-shock proteins known to elicit humoral response both in 
cancer  patients  and  patients  with  autoimmune  diseases  but  the  rest  of  the  natural  ORF 
antigens  have  not  been  previously  implicated  in  autoimmune  responses.  However,  the 
majority of the serum-reactive clones contained cDNAs fused to the phage coat protein 10B 
in a different reading frame, 5’ or 3’ UTRs, ribosomal RNA genes or mitochondrial DNA, 
thus expressing 4 to 80 aa long peptides that likely represent mimotopes. The nature of the 
antigens  they  represent  is  not  known as  they  may  mimic  protein  as  well  as  non-protein 
antigens of cancer or normal cells or various pathogens.
The main objectives of the current study were:
• To develop technology for the production and processing of phage displayed antigen 
microarrays.
• To evaluate the performance of support vector machine (SVM) with improved kernel 
for the generation of biomarker models for the diagnosis of cancer.
• To develop procedures for the normalisation of microarray data, defining cutoffs that 
allow to discriminate between sero-positive and sero-negative cases, and ranking of 
antigens considering the signal intensity and the frequency of reactivity.
• To apply the phage displayed antigen microarray technology and the data analysis 
approach  for  the  exploration  of  autoantibody  profiles  in  gastric  cancer  and 
identification of autoantibody signature with the diagnostic relevance, and assessment 
of humoral  responses  in  patients with various  cancers  against  a  family of sperm-
associated antigens (SPAG). 
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 1. LITERATURE OVERVIEW
 1.1 . Nature of Cancer
Cancer or malignant neoplasm is the class of diseases defined by uncontrolled growth of 
cells and formation of metastasis (10). Cancer development is a complex multistage process, 
associated with the aggregation of genetic and epigenetic changes in the cells, leading to the 
transformation of normal cell into the cancer (11).
In 2000, Douglas Hanahan and Robert A. Weinberg have proposed six major features 
(“hallmarks”)  acquired  by cancer  cells:  self-sufficiency in  growth signals,  insensitivity  to 
antigrowth signals , evading apoptosis , limitless replicative potential, sustained angiogenesis 
and tissue invasion and metastasis (12).
Self-sufficiency in growth signals.
The  ability  to  unlimited  proliferation,  sustained  by  proliferative  signal,  is  the 
fundamental  characteristic  of  cancer  cells.  Cells  of  multicellular  organisms  require 
extracellular signal to move to proliferative state. This prohibition can be bypassed in four 
ways. The necessary growth factors can be produced by cells themselves,  the signal can be 
received from normal cells of cancer-associated stroma, which supplies the cancer cells by 
various growth factors or the signal can be enhanced by amplification of cell surface receptors 
as well as by acquisition of independence from growth factors (13,14). The structural change 
of  receptor  molecule  or  persistent  activation  of  components  of  signaling  pathways 
downstream from receptor in the circuit can be as example of such independence.
Insensitivity to antigrowth signals .
Cellular homeostasis is maintained in the tissue through the correct responses to inter-, 
extra-, and intracellular antigrowth signals. In normal cells, TGF-β, acting through signaling 
network, stops the cell cycle, induce differentiation, or trigger apoptosis. Cancer cells bypass 
this  replicative  barrier,  and  acquire  the  ability  to  divide  indefinitely  by  mutations  or 
downregulation  of  TGF-β receptors,  inactivation  of  SMAD4 or  p15INK4B (15). TGF-β due 
these  changes  frequently  convert  from  a  supressor  of  tumor  formation  to  promother  of 
metastasis in late stage tumors  (15).  Contact inhibition is a process of arresting cell growth 
when two or more  cells come into contact with each other. Cancer cells typically lose this 
property due deregulation of LKB1 or Merlin pathways (16,17).
Evading apoptosis .
The cells can induce the senescence or apoptosis as the response on the excessively 
elevated signaling. Consequently, the relative intensity of proliferative signaling in tumor is a 
compromise between stimulation  of  growth and escape  of  these  antiproliferative  defense. 
Cancer cell may try to avoid limitation by changes in pathways of senescence or apoptosis 
(18,19). The inactivation of tumour suppressors is common in cancers and can be detected in 
majority of malignant tumors. Because activation of tumour suppressors, such as TP53, can 
halt a cellular cycle or trigger the program of apoptosis, it is necessary for a cancer  cell to 
inactivate them. The TP53 regulates the transcription of many different genes in response to a 
wide variety of stress signals or abnormality sensors (20). The cell can also loose the function 
of TP53 itself  or increases the expression of antiapoptotic regulators (Bcl-2) and survival 
signals (21). The proliferative signaling can be enhanced by the defects of negative-feedback 
loops, normally involved in homeostatic regulation (22).
Limitless replicative potential.
The telomerase, specialized DNA polymerase responsible for lengthening of the ends of 
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telomeric DNA, was detected in overwhelming majority of cancer cells the opposite to normal 
differentiated cells where it is not expressed (23). The telomeres play a key role in the ability 
of unlimited proliferation as suspected in different observations. So it is extremely important 
that the activity of telomerase is enabled by cancer cells. Perhaps the induction of telomerase 
is  delayed or  increases  gradually,  and due  this  process  the  cancer  cell  can  get  necessary 
genetic  instability  by  deletion  of  chromosomal  segments  (24).  The  enhancement  of  cell 
proliferation, involvement in DNA repair and resistance to apoptosis are another additional 
features of telomerase (25,26).
Sustained angiogenesis.
The ability of tumour to induce the angiogenesis (process of formation of blood vessels) 
is another  important factor for tumour growth up to macroscopic size. Known inducers of 
angiogenesis as VEGF-A and TSP-1 upregulated in the tumor tissues chronically (27,28).
Tissue invasion and metastasis.
The process of invasion and metastasis includes the following steps: the local invasion, 
the intervasation into the surrounding blood and lymphatic vessels, the escape of cancer cells 
into the parenchyma of distant tissues, the foundation of small nodules and finally growth of 
micrometastases  into  the  macroscopic  colonies  (29).  The  cancer  cells  get  the  necessary 
properties using the program of epithelial-mesenchymal transition. Normally this program is 
used by fetal cells at the earliest stage of formation of body and differentiation of multiple  
tissues, as well as for the wound healing and repair of adult tissues (30). The existence of 
interaction between the distant metastases, primary tumor and cells of tumor stroma as well as 
its  importance in  metastasis  has  been shown in many observations  (31).  The majority  of 
disseminated cancer cells are not entrenched in the new tissues due to changed conditions, 
which they have not been adapted to. One of opinion is that in case of new environment these 
cells need to create a new set of features for adaptation. As the result the development of other 
types of cancer and following reverse metastasis into primary tumour occurs (32,33).
Figure 1. The hallmark features acquired by cancer cells. Adapted from Hanahan & 
Weinberg, 2011.
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The modern theory extend the list of the features acquired by most of cancer cells by 
including two additional hallmarks: reprogrammed energy metabolism and avoiding immune 
destruction.  Genome  instability  and  tumour-promoting  inflammation  were  established  as 
enabling characteristic, that assist in obtaining of other hallmarks (34).
Reprogrammed energy metabolism.   
In actively growing tissues, such as fetal tissue and tumours, metabolic regulation tends 
to differ from the normal adult tissues. They consume more glucose to produce lactate, even 
in the presence of ample oxygen. This phenomenon, known as the Warburg effect, enables 
rapidly dividing tumor cells to generate essential biosynthetic materials such as nucleic acids, 
amino acids and lipids from glycolytic intermediates (35).
Avoiding immune destruction.
Several lines of evidence suggest that at  the beginning when genetic and epigenetic 
structural  changes  occurs  in  a  single  cell,  the  pre-neoplasm will  be  destroyed in  case  of 
significant  immunogenicity  and  active  immune  system.  The  cancer  with  high  amount  of 
genetic changes contains new antigenic epitopes generated due to the expressed proteins. The 
immune system is able to recognize such tumour cells, classify them as foreign and activate a  
protective  response,  although the  tumour  cells  are  capable  to  develop characteristics  that 
allow avoid the immune response (36).  Tumors can escape from the immune response by 
process called immunoediting. This process consists of three phases: elimination, equilibrium 
and escape (37,38). 
Figure 2. Cancer immunoediting include three process. (a) Elimination corresponds to 
immunesurveillance. (b) Equilibrium represents immunoselection of tumour cell variants with 
increasing capacities to survive immune attack. (c) Escape is the process wherein the 
immunologically sculpted tumour actively suppress the immune response and expands in the 
immunocompetent host. In panel a and b: developing tumour cells (blue), tumour cell variants 
(red), underlying stroma and nontransformed cells (grey), cytokines (small orange circles), 
white flashes represent cytotoxic activity of lymphocytes against tumour cells. In panel c: 
additional tumour variants (orange) that succeed to overcome immune pressure. Adapted from 
Dunn, Bruce, Ikeda, Old & Schreiber, 2002.
During  the  elimination  phase,  tumor-specific  antigens  trigger  an  immune  response, 
which leads to the destruction of neoplastic cells,  preventing development of cancer.  The 
equilibrium  phase  of  immunoediting  describes  a  dynamic  balance  between  the  immune 
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system’s containment of the tumor and acquisition of immune evasive strategies by subsets of 
cancer  cells  (39).  Cancer  cells  evade  immunesurveillance  via two  general  ways: 
immunoselection  and  immunosubversion.  Immunoselection  is  a  selection  of  non-
immunogenic tumour-cell variants. This process leads to down-regulation of MHC molecules 
or loss of expression of antigens recognized by the immune system and therefore reduced 
immunogenicity. Immunosubversion is a process by which tumor cells suppress the immune 
system through a complex network, leading to specific or generalized tolerance. The immune 
system  contributes  to  tumor  progression  by  selecting  for  the  most  aggressive  clones  or 
stimulating  tumor  cell  proliferation  (40). The  tumor-induced  tolerance  is  associated  with 
expansion of non-functional T cells and suppression of other immune effector cells (41).
Genome instability.
The  genes  regulating  cell  growth  and its  differentiation  must  be  altered  within  the 
transformation process of normal cell into the cancer cell. Genetic changes can be caused by 
carcinogenic  factors  –  the  radiation,  the  chemicals,  infectious  pathogens  and  specific 
endogenous reactions such as respiration and oxidative lipid peroxidation (10). The mutations 
can  be  accumulated  by  cells  in  case,  when system of  DNA repair  fails  (10).  Epigenetic 
changes  have  been shown to play equally  important  role  in  the  formation  of  malignancy 
(42,43). DNA methylation  pattern  in  the  cancer  cell  is  altered  leading  to  genome-wide 
alterations  in  the gene expression profiles  as well  as  may contribute to  the chromosomal 
instability  (44). Epigenetic  changes  have  been  detected  in  the  early  stages  of  tumour 
formation and also in the normal tissues prior transformation to the cancer cells. 
Tumour-promoting inflammation.
Paradoxically, the recent studies show that many immune system cells as macrophages, 
neutrophils  and  mast  cells,  as  well  as  myeloid  progenitors  infiltrate tumour  and  help  to 
maintain the angiogenesis as well as release the growth factors (27). The local tissue damage 
due to increased cell mass pressure on the surrounding tissues takes place at the time when the 
tumour is  getting bigger  and the tissue homeostasis  is  disturbed.  As a  result  a  variety of 
inflammatory factors, attracting immune cells have been produced. This leads to release of 
cytokines,  chemokines  and  reactive  oxygen  compounds  by  macrophages  and  mast  cells 
inducing the inflammation and infiltration of other immune cells, such as dendritic cell, into 
the tumor. The inflammatory process and formation of a stroma around the tumour can be 
induced by recruiting cells of innate immune system and normal cells of surrounding tissues. 
These cells,  as recent studies show, are active participants  in the process of formation of 
cancer, rather than passive bystanders (34). Due to inflammatory process these cells form the 
tumour associated stroma, providing the growth and survival factors, inducing the signals of 
activating of EMT and even acting as immunosuppressors  (31,45). The modern theories of 
carcinogenesis  suggest  consider  the  cancerous  tumour  and  surrounding  supportive 
microenvironment joined (34).
It  is  well  known that  solid  tumours are  heterogeneous by histological  structure and 
consist  of  a  variety  of  tumour  cells,  the  surrounding  stroma,  the  vasculature,  and 
inflammatory infiltrates, etc. Besides the populations of different types of cells present in the 
hematological malignancies as well as in the solid tumours, the subpopulation of cells with 
properties of stem, known as cancer stem cells (CSC), has been found. Subsequently,  the 
cancer  stem  cell  theory  of  carcinogenesis  was  created  (46-48).  This  cell  population  is 
responsible  for  the  following  features  of  the  tumour:  the  ability  to  self-regeneration,  to 
metastasize,  and  recur  of  infiltrative  growth,  as  well  as  resistance  to  chemotherapy  and 
radiation treatment (49,50). The CSC can differentiate into a variety of cell types depending 
on the origin of tissues (51). Most of the studies show that CSCs is only a small minority of 
11
the cells in a cancer (52), however in some cases of melanoma the CSC proportion can reach 
even 25% (53). The wide variation of proportion of CSC (from 20% to virtually all cells) has 
also been demonstrated in a colorectal cancer study (54). There is a hypothesis that these cells 
are formed by normal  stem cells  or progenitor cells  as a result  of transformation process 
influenced by mutations or epigenetic changes (55).
 1.2 . Biomarkers
Biomarkers can be defined as a parameter that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention. The cancer biomarkers might be secreted by tumour itself or by 
the body as specific response to the cancer. For cancer diagnosis, prognosis and epidemiology 
the genetic, epigenetic, proteomic, glycomic and imaging biomarkers can be used.
The significant genetic, chromosomal and epigenetic changes as well as deregulation of 
the processes  of  splicing,  translation  and the activation  of  microRNA are  ongoing in  the 
cancer  cells.  This  leads  to  appearance  of  protein  atypical  for  normal  tissues  and  wide 
oscillations of expression level of protein, found in normal tissues in small amount. These 
markers can be assessed in the biofluids collected non-invasively.
The tumour diagnostic biomarkers are used for general population screening, tumour 
volume  estimation,  differential  diagnosis  in  symptomatic  patients  and  clinical  staging  of 
cancer.  Predictive  biomarkers  help  to  evaluate  treatment  response.  Prognostic  biomarkers 
indicate disease progression regardless of the type of treatment or lack of treatment  (56). 
Unfortunately, there are not many reliable serum biomarkers currently in use at the clinic and 
tissue-based  markers  require  an  invasive  procedure  to  obtain  the  samples  for  diagnostic 
purposes. However, majority of tumour biomarkers has low sensitivity, as its expression is 
increased in fewer than 50% of early-stage for most studied markers, as CA125 for ovarian 
cancer that has also been proposed as a possible screening test for this disease.(57,58).
One of the well – known examples of biomarkers widely used in diagnostic population 
screening is Prostate-Specific Antigen (PSA). It is a tumor marker discovered in 1980 and 
routinely tested in blood samples  (59). The PSA is not prostate cancer specific and may be 
present  in  the normal  prostate  at  the same levels  as  in  the prostate  cancer.  Despite  these 
limitations, the PSA screening has been implemented to the practice, although 17% of men 
with normal levels of PSA in blood have cancer cells within the prostate  (60), and 78% of 
men, who has PSA level higher than 4 ng/ml, do not have prostate cancer (61). Many early 
stage  patients  with  prostate  cancer  undergo  radical  treatment  due  to  the  lack  of  reliable 
biomarkers, which would allow to differentiate aggressive cancers from the relatively indolent 
and slowly progressing cancers (62).
Serum pepsinogen test based on the combination of the serum pepsinogen I level and 
pepsinogen  I/II  ratio  and  presence  of  Helicobacter  pylori are  the  known biomarkers  for 
diagnosis  of  gastric  cancer.  They  both  quantitative  biomarkers  and  show  relatively  low 
specificity. Serum pepsinogen test show a sensitivity 77% and specificity 73% at pepsinogen I 
level < or = 70 ng/ml and pepsinogen I/II ratio < or = 3 (63). SPT has strong correlation with 
intestinal-type cancer (63).
A list of known serum gastric cancer biomarkers includes CEA, CA 19-9, CA50 and CA 
72-4, all of which exhibit generally low sensitivity (<50%), especially for early stages (<20%) 
of  GC (64-68).  However,  these  biomarkers  are  shared  between  different  types  of  cancer 
showing higher frequency in other, such as pancreatic, cancers (69).  Not surprisingly, such 
biomarkers don't have a significant role in gastric cancer diagnosis and screening and are 
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more frequently used  for the prognosis of recurrence after resection (64-68,70).
Several observations attribute to the CEA, CA19-9, CA50 and CA72-4 highest diagnostic 
accuracy 0.53, 0.64, 0.59 and 0.75, respectively (64-68,71-73).
 1.3 . Autoantibodies
The  tolerance  against  self-antigens  is  the  critical  function  of  immune  system.  The 
breakdown  of  self-tolerance  leads  to  autoimmune  disease  involving  appearance  of 
autoantibodies, chronic inflammation and tissue destruction. The presence of autoantibodies is 
not  exclusive  for  autoimmune  disease.  Most  if  not  all  patients’ cancer  sera  contains  the 
antibodies  against  tumor-derived  proteins  (3,74).  The  autoantibody  repertoire  is  very 
heterogeneous and shared between cancer and autoimmune disease patients (6). The humoral 
immune response against self-antigens has the same features as the immune response referred 
to foreign antigens: high specificity to antigen, affinity maturation and immunoglobulin class 
switch from IgM to IgG (75).
If the immunosurveillance is a general phenomenon, the immune response is likely to 
occur before a clinically detectable cancer (37). In fact, several observations indicate that the 
antibodies  to  tumor-associated  antigens  occur  long before  the  clinical  symptoms  (76-78). 
However, the mechanisms of production of autoantibodies and their biological significance 
are  not  completely  understood.  Many  evidences  show  remarkable  association  of  chronic 
inflammation and the development of cancer (6,9).
The  only  small  part  of  autoantibodies  react  with  antigens  exclusively  expressed  in 
cancer  cells,  more  frequently  the  autoantibodies  recognize  the  self-antigens.  The  tumour 
specific antigens can be divided into the oncogenic viral proteins and altered proteins (neo-
antigens), which appear in the cancer cell due to the genetic instability and deregulation of 
mRNA splicing (79). Tumor-associated antigens include overexpressed proteins that normally 
are expressed at very low levels.  
The autoantibodies against many TAA, for example CTAG1B, TP53, c-MYC, cyclin B1 
have been found in patients with different type of cancer (80). The cancer-testis (CT) antigens 
normally are expressed only in the immune-privileged tissues or during the fetal development. 
Autoantibodies against CT antigens have been associated with a poor prognosis. Antibodies to 
NY-ESO-1 (one of the CT antigens) has been shown to correlate with volume of tumour 
present in body (81), progression of disease  in melanoma (82) and lower overall survival in 
prostate cancer (83).
The antigen p53 represents  one  of  the best-studied tumor  antigen.  The TP53 tumor 
suppressor gene is a protein most frequently mutated in human cancers.  Because mutated 
TP53 can induce an immune response and can occur early in the carcinogenic process for 
some tumors, p53 autoantibodies are the remarkable diagnostic biomarkers of cancer (84). 
Several studies indicate correlation between p53-specific autoantibodies and decreased overall 
and  progression  free  survival  in  breast,  lung,  colon,  and  oral  cancer  (85,86),  but  in 
hepatocellular carcinoma, it has been suggested that the presence of p53-specific antibodies is 
associated with the increased overall  survival,  when compared with the antibody-negative 
patients (87).
Autoantibodies to CEA, CML66 and SOX1 show correlation with better outcomes in 
cancer patients (88-90).
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 1.4 . Microarray technology
Since its invention in 1995 (91), the microarray technology has become a principal tool 
for high-throughput detection of gene expression and analysis within scientific research and 
clinical studies. The microarray consist of an arrayed series of microscopic spots with a small 
amount  of  either  DNA, protein,  or  carbohydrate  target  molecules  immobilized on a solid 
medium (generally glass or plastic slides). Whichever the immobilized molecule in a probe is, 
all microarrays are based on the same principle as southern and dot blot is: the affinity of a 
sample  to  the  probe  allowing  the  evaluation  of  molecule/molecule  interactions,  but  in 
comparison  to  a  dot  blot,  microarray  has  a  much  larger  scale.  The  possible  pairs  of 
interactions are DNA/DNA, DNA/protein, protein/protein, antigen/antibody and others. The 
samples such as serum specimen are labeled by the fluorescent tag molecule. The molecules 
immobilized in the microarray can then bind the target if present. The pattern of fluorescence 
is representative of the sample under test. This technology allows to test thousands of probes 
simultaneously.  The  commercial  DNA microarrays  can  have  up  to  4.2  million  features 
(Nimblegen 4.2M CGH arrays)  allowing the evaluation of the whole genome in a  single 
experiment.
The applications of protein microarrays include the expression profiling, serum-based 
diagnostics, protein / protein binding assays, and drug / target binding. Three different kinds 
of  protein  microarrays  currently  exist:  the  analytical  protein  microarrays,  functional 
microarrays,  and  reverse-phase  microarrays.  The  analytical  protein  microarrays  are 
constructed by arraying of antibodies or non-folded antigens on a glass slide, which is then 
tested with a protein solution. This methodology is used to measure protein expression levels 
in a solution, similar to the sandwich ELISA technique. The functional protein microarrays 
consist  of  a  full  proteins  or  protein  domains  attached  to  a  layer  of  a  porous  polymer 
(polyacrylamide, agarose, or gelatine) on solid medium. They are used for studying protein 
interactions  with  other  proteins,  macromolecules,  or  small  molecules.  The  reverse  phase 
protein microarrays (RPMA) correspond to the miniaturization of dot blot. In RPMA, proteins 
of interest  such as recombinant  proteins  in purified form or in cell  lysates or plasma are 
spotted onto a glass slide, and then the arrayed targets are tested by using antibodies against 
the protein of interest or sera. The complexity in comparison to DNA microarray is the main 
challenge of protein microarrays.
Although  RPMA may  be  viewed  by  some  experts  as  the  microarray  technology 
analogous to DNA microarrays, protein microarrays are technically in a distinct class due to 
the signal variability across the array (92).  DNA microarrays are expected to have virtually 
identical mRNA levels for all samples, whereas protein microarrays can be markedly different 
total protein and target protein concentrations in different samples (92). The concentration of 
a protein is important for signal-to-noise ratio.
The  technical  variations  occurred  at  manufacturing,  processing  and  scanning 
microarray, such as probe labelling, incubation conditions, washing, signal and background 
detection, slide surface and batch effects, lead to a biased analysis of microarray data.
The normalization algorithms for microarray data include two different steps: within 
array and interarray normalizations. Within array step can include global and/or local types. 
The conventional methods for intra-slide normalisation are global, quantile  and LOWESS 
normalizations.
All normalization algorithms assume that less than 20% of probes vary between arrays. 
Traditionally for verification and visualization of quality of normalized data use MA plots 
where on the X axis: A= (log2R + log2G)/2 and on the Y axis:  M= log2R-log2G.
The global normalization refers to method where intensity of each spot is scaled by an 
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array specific constant so that the mean/median of all arrays is the same.
The quantile normalization suggests that the intensities of each array have the same 
distribution. For the quantile normalization the highest value on all arrays becomes the mean 
of  the  highest  values,  the second highest  value becomes the mean of  the second highest 
values, and so on.
LOWESS stands for Locally Weighted Linear Regression. It is based on the MA plot. It 
takes in all the data points, log transforms data and fits them to localize linear regression line. 
Then, the cut-off is applied, dismissing spots whose signal and control are both below the cut-
off (93).
The conventional methods of the analysis of microarray data is a fold change, t-test, 
analysis  of  variance  (ANOVA),  clustering,  regression  analysis,  maximum  likelihood  and 
classification.  The  most  widely  used  classifiers  are  Artificial  Neural  Networks,  Gaussian 
Mixture Models, Naive Bayes, Decision Trees, RBF classifiers, K-Nearest Neighbours and 
Support Vector Machines.
The  Support  Vector  Machines  (SVM) dominates  as  the  most  popular  technique  for 
multicategory  classification  of  microarray  data (94),  significantly  out  performing  other 
classifiers. The Support Vector Machines is the “state-of-the-art” machine leaning approach 
that uses Statistical Learning Theory for successful implication of the best possible separation 
of two classes in the binary classification task. This approach could be easily extended for the 
multicategory classification purposes as well. The basic idea of SVMs is inferred as follows: 
find two parallel hyperplanes in the hypothesis space with the largest possible margin such 
that the majority of data points of the class “+1” is located in the first half-space (separated by 
the first  hyperplane)  and the majority  of  other  data  points (denoted by class “-1”)  in  the 
second half-space (NB: we should note that in between of these half-spaces exists a margin-
area that is maximized by the SVM optimization problem). The extensions of SVM method 
suppose  hard-margin,  soft-margin  cases  as  well  as  a  nonlinear  separation  using  so-called 
“kernel trick” that transfers initial hypothesis space to possibly infinite one with perfectly 
available separation. This trick enables SVM with direct embedding of similarity measures 
encoded into kernels via “kernel trick”. As close is this measure to the original classification 
problem and original distributions of similarity among samples as precise and accurate will be 
final generalization ability of SVM. For more detailed information about theory of SVMs or 
applications for microarray data analysis refer to (94,95).
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 2. MATERIALS AND METHODS
 2.1 . Serum samples
Serum samples and information about the clinical status of patients with melanoma, 
gastric,  lung,  breast  and prostate  cancer  as  well  as  healthy  individuals  and patients  with 
gastric inflammatory disease were received  from  Genome Database of Latvian population. 
Another set of sera of patients with gastric cancer were collected at Latvian Oncology Center 
and  Clinic  of  Gastroenterology,  Hepatology  and  Infectious  Diseases,  Otto-von-Guericke 
University Magdeburg, Germany.
The serum collection includes 39 breast, 24 lung, 339 gastric, 52 prostate cancer, 190 
melanoma, 313 healthy controls, 150 patients with gastric inflammatory disease.
All samples were stored at -80oC.
The tissue and serum specimens were collected after the patients’ informed consent was 
obtained in accordance with the regulations of Committee of Medical Ethics of Latvia and the 
ethical committee of the Otto-von-Guericke University Magdeburg.
 2.2 . Printing protocol
E.coli BLT5615 cells  were  grown from fresh  culture  until  OD600 reached  0.8,  the 
expression of the phage coat protein 10B was induced by IPTG for 30 minutes, aliquoted in 
96  deep-well  plates  (Whatman,  500mkl  per  well)   and  infected  with  5mkl  of  low-titre 
monoclonal  phage stocks,  grown at  37  oC, 220 rpm until  complete  cell  lysis.  Then 6.4% 
glycerol was added and plates were centrifuged to remove cell debris and subjected to PCR-
based quality control. The lysates were clarified by centrifugation and arrayed in 2 replicates 
onto  nitrocellulose-coated  FAST  slides  (Whatman)  with  a  QArray  Mini  microarrayer 
(Genetix) using a protocol adapted for printing protein microarrays: 
maintained air humidity 45-55%, 
DNA microarray protocol with the following wash cycle of needles: 
4x 1.5s 0.05% Twееn 
4x 1.5s double distilled water.
 2.3 . Processing of antigen microarrays
Dry slides for 30 min at +37oC, store at +4oC;
Day 1:
 Make serum dilutions 1:200 in TBS, 0.5% Marvel: 
Prepare 5% Marvel in TBS, 0.05% Tween (0.5g/10ml)
Serum-dilution buffer (7 ml):5.7 ml TBS
0.7 ml 5% Marvel
0.3 ml E. coli-T7 phage lysate
0.3 ml E. coli-T7-C3-Strep phage lysate
Aliquot 200 µl in 2.2 ml deep-well plates +1 µl serum 
Incubate on shaker (200 rpm) at +4oC.
Day 2:
 Blocking: 7% Marvel in TBS, 0.05% Tween (0.7g/10ml TBS, 0.05% Tween). 
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Put slides in incubation plates, pour over blocking buffer (10ml for 10x10cm plates), 
incubate 1h, RT, 38 rpm on shaker. Pour off the blocking solution and briefly wash in 
TBS-0.5% Tween.
 Put the slides in incubation chambers & Fast frame.
 Serum: 
o Cf the serum plate at 3000 rpm for 10 min
o Add 80 µl of the diluted & preabsorbed serum per well, incubate for 2h, RT, 38 
rpm on shaker
o Pipette off the serum, rinse the chambers 3 × with 0.1 ml TBS-0.5% Tween 
using 8-channel pipette, take out the slides from the incubation chambers, put into the 
High  Throughput  washing  chamber  and  wash  4×15  min  in  TBS-0.5%  Tween  on 
magnetic stirrer.
 T7 tail antibody:
o Prepare T7 tail antibody dilution 1:10 000 in TBS, 0.5% Marvel
o prepare 63 ml Ab dilution buffer: 58.5 ml TBS + 4.5 ml 7% Marvel
o 3 µl T7 tail antibody + 30 ml Ab dilution buffer
 Put the slides back in the incubation plates
 Put 10ml Ab for 8x8cm plate, incubate for 45 min, RT, 38 rpm on shaker
 Pour off the Ab, wash 4 ×10 min in chambers.
 Secondary antibodies: 
o Cy5 conjugated Goat Anti-Human IgG (minimal cross-reaction with bovine, 
horse,  mouse  serum  proteins)  (Jackson  ImmunoResearch,  #109-175-098)  1:1500 
diluted in Ab dilution buffer
o Cy3 conjugated Goat Anti-Mouse IgG (minimal cross-reaction to human serum 
proteins) (Jackson ImmunoResearch,  # 115-165-071) 1:3000 diluted in Ab dilution 
buffer
o 30 ml Ab dilution buffer
o 40 µl Cy5 conjugated Goat Anti-Human IgG 1:2 dil. glycerol stocks
o 20 µl Cy3 conjugated Goat Anti-Mouse IgG 1:2 dil. glycerol stocks
 Put the slides back in the incubation plates
 Put 10ml Ab for 8x8cm plate and 4.5ml for black tray, incubate for 45 min, RT, 
38 rpm on shaker
 Pour off the Secondary Ab, put the slides into the High Throughput washing 
chamber and wash 4×15 min in TBS-0.5% Tween on magnetic stirrer, rinse one in 
dist. H2O and dry by centrifugation for 1 min at 1000 rpm. Wash the chambers with 
detergent, rinse in dist. H2O and dry.
 2.4 . Data processing and analysis
Slides scanned on Tecan Power Scanner with 532 and 635 nm lasers at 10m resolution 
and the images were saved as TIFF files.
The  spot  data  were  extracted  by  GenePix  Pro  software  using  the  proprietary  spot 
recognition  algorithm.  R-language  software  (96) with  additional  packages:  limma(97), 
marray, ROCR, OLIN(98), survival, verification, REvolution R were used for following data 
processing and computational analysis.
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Median foreground and background intensities, as well as median, mean and standard 
deviation of Cy5/Cy3 ratios for pixels within a spot were obtained for each spot and imported 
into the script developed in-house. The dataset was filtered to remove unqualitative spots sets 
within print batch that for more then half of set had high morphological heterogeneity (for 
Cy5/Cy3 ratios of pixels within a spot: ratio standard deviation to mean bigger then 1.5 or 
difference  mean  and  median  more  then  50%)  and  any  elements  that  had  been  manually 
flagged as poor quality.
The  signals  Cy3  and  Cy5  were  separately  normalized  within  a  each  slide  by  data 
centering  on the basis of middle 80% of intensities (median of this set on each channel will  
be zero and the standard deviation will be 1).
Interslide normalization was performed for each antigen spots series within printing 
batch by data centering on the basis of middle 80% of intensities (median of this set on each 
channel will be zero and the standard deviation will be 1).
Cy5/Cy3 ratios were calculated and averaged between replicates.
The threshold value (T) for each antigen was calculated as follows:
 , where IHD is the signal intensities in healthy controls. 
Then the rank for each antigen rank was calculated, on the base of intensities of positive 
signals  within  gastric  cancer  patients  compared  to  healthy  donors,  using  the  following 
formula: 
Finally, a score for each serum was calculated as follows: . 
Support Vector Machine
All measurements and experiments were performed using MATLAB framework  (99) 
and some highly robust and optimized linear algebra packages: LAPACK (100), Metis, Ipopt. 
As  the  reference  implementation  of  SVM  algorithm  another  highly  recognized  calculus 
package  was  used:  LibSVM  (101).  As  the  cornerstone  of  our  implementation  was 
SimpleMKL  framework  (102).  We  used  it  extensively  for  identification  of  optimal 
hyperparameters of RBF kernel and our proposed Ranking-Based kernel.
18
 3. RESULTS
The current dissertation is based on the following original publications referred in the 
text by their Roman numerals. The author's contribution to the enclosed original publications:
Original paper I
Kalniņa Z,  Siliņa  K,  Meistere  I,  Zayakin  P,  Rivosh A,  Ābols  A,  Leja  M,  Minenkova O, 
Schadendorf  D and  Linē  A.  Evaluation  of  T7  and Lambda  phage  display  systems  for  survey of 
autoantibody profiles  in cancer patients.  J Immunol  Methods,  2008 May 20;334(1-2):37-50.  Epub 
2008 Feb 21
Contribution: development of the methodology for the production of phage-displayed 
antigen  microarrays,  development  of  the  data  normalization  method,  scanning,  data 
acquisition, normalization and statistical analysis.
Original paper II
V. Jumutc* ,  P. Zayakin*  , and A. Borisov.  Ranking-based Kernels in Applied Biomedical 
Diagnostics using Support Vector Machine. International Journal of Neural Systems, (accepted).
* The first two authors contributed equally to this work 
Contribution:  development  of  normalization  approach  and  idea  of  ranking-based 
kernel, preparation of data, the graphical information and partially manuscript.
Original paper III
K.  Silina,  P.  Zayakin,  Z.  Kalnina,  L.  Ivanova,  I.  Meistere,  E.  Endzelins,  A.  Abols,  A. 
Stengrevics, M. Leja, K. Ducena, V. Kozirovskis, A. Linē. Sperm associated antigens as targets for  
cancer  immunotherapy:  expression  pattern  and  humoral  immune  response  in  cancer  patients .  J  
Immunother, 2011, Jan;34(1):28-44.
Contribution:  production  of  phage-displayed  antigen  microarrays,  development  of 
approach  for  the  data  normalisation  and  determination  of  cutoffs,  data  acquisition, 
normalization and statistical analysis.
Original paper IV
Zayakin P, Kalniņa Z, Siliņa K, Meistere I, Ivanova L, Endzeliņš E, Jumutcs V, Stengrēvics A,  
Leja M, Wex T and Linē A.  Tumour-associated autoantibody signatures for the early detection of 
gastric cancer (submitted to Cancer Prevention Research)
Contribution: development of normalization approach and ranking based procedure, 
production  of  phage-displayed  antigen  microarrays,  data  acquisition,  normalization  and 
statistical analysis, preparation of data and the graphical information.
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 3.2 . Development of phage-displayed antigen microarray
In order to establish and optimize the technique for the production of PhD-AM, the 
following issues were addressed:
Choice of slide surface chemistry. A test set of 380 phage clones comprising 335 sero-
reactive  clones  and  45  non-recombinant  T7  phage  clones  was  assembled,  amplified  and 
printed  on slides  coated with different  surface:  epoxy,  aldehyde and nitrocellulose coated 
slides produced by two different companies. The slides were tested with serum and anti-T7 
antibodies and spots morphology and signal-to-noise ratios were compared. For this study we 
selected nitrocellulose coated FAST slides produced by Whathman, that showed the best spot 
morphology and highest signal to noise ratio.
Choice of method for the amplification of phages. Plate lysates, 3 ml liquid culture 
lysates in individual tubes with or without subsequent precipitation with PEG/NaCl, and 0.5 
ml liquid culture lysates in deepwell plates were prepared, spotted on FAST slides and tested 
with  anti-T7  antibody.  The  phages  that  were  grown  in  deepwell  plates  showed  the  less 
variation in spot size and intensity across the array therefore this amplification method was 
used for the rest of the study.
Antibody dilutions. Series of experiments were performed in order to determine the 
optimal dilutions of serum, anti-T7 antibody and secondary antibodies. The best signal-to-
noise ratio was observed when 1:200 diluted serum, 1:1000 diluted anti-T7 antibody, 1:1500 
anti-human IgG and 1:3000 anti-mouse IgG secondary antibodies were used.
Serum preabsorbtion. Pre-incubation of serum with E. coli and T7 phage lysates for 1 
hour before putting it  on a slide significantly reduced the non-specific Cy3 signal (serum 
reactivity  against  phage and  E.  coli proteins)  and increased  the  Cy3/Cy5 signal  ratio  for 
positive  clones,  therefore  we  concluded  that  serum pre-absorption  is  an  essential  step  in 
microarray  processing  protocol.  To  standardise  this,  large  amounts  of  E.  coli and  phage 
lysates were prepared and the same batch of lysates was used all the way through the study.
Printing conditions. The conventional procedure for printing DNA  was amended due 
to the differences in the chemical properties of DNA molecules and proteins. The results of 
our tests have shown the need to use lower levels of humidity (45-55%) and the catastrophic 
deterioration of spots in case of use of ethanol in a cycle of needle washing. The  E. coli 
lysates tend to form deposits on the surface of the needles. This sediment was fixed by ethanol 
during washing cycle and could not be removed by the following wash cycles. Therefore 
0.05% Tween has been entered to the wash cycle and the ethanol solution has been replaced 
by distilled water.
Data acquisition. The slides were scanned on AQuire scanner (Genetix) with 532 and 
635 nm lasers at 10m resolution with as the highest possible PMT gain that did not shown 
the  saturation.  The  spots  data  has  been  extracted  by  GenePix  Pro  software  using  the 
proprietary  spot  recognition  algorithm.  The analysis  of  data,  passed  the  normalization  as 
described below, shows the variation of not more than 3% for arrays scanned in a fairly wide 
range  PMT gains  in  the  absence  of  saturated  spots.  The  following  data  processing  and 
analysis was made in ad hoc composed scripts using R-language software (96).
By addressing the above mentioned issues, the protocol for production and processing 
of antigen microarrays was developed. In order to validate the assay, the set of 380 phages 
was printed on FAST slides and tested for reactivity with the same set of 22 sera that was used 
for TA mini-library and macroarray screening and sera from 8 healthy donors. Median of Cy3/ 
Cy5  ratios  was  calculated  for  each  spot  and  averaged  between  replicates.  For  local 
normalization  LOWESS  were  used.  In  order  to  normalize  the  signal  intensities  among 
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different arrays, an average Cy3/Cy5 ratio for all wild-type phage spots in an array was set to 
be equal to 1 and the values for the rest of the spots were re-calculated accordingly. A positive 
cut-off value was set as 3 -4 SDs above the average for wild type phage spots in each array.  
Using these settings, 70-90% of phages that were positive in  plaque assay screening were 
defined as positive by microarrays. Lowering the cut-off value resulted in better sensitivity 
but increased a false positive background.
The intra-assay variability of the phage-displayed antigen microarray technology was 
7%, while  the  average CV was ~13% in  the  inter-assay  comparisons,  which is  generally 
acceptable variability for immunoassays (103).
Plaque assay and PhD-AM turned out to  have comparable,  presumably due to  high 
difference in conditions of adsorbing phage particles onto nitrocellulose. In some cases PhD-
AM demonstrate even slightly lower sensitivity than the plaque assay.
 Figure 3. Comparison of sensitivity of PhD-AM technology and plaque assay.
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 3.3 . Ranking-based Kernels in Applied Biomedical  
Diagnostics using Support Vector Machine
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 3.5 . Tumour-associated autoantibody signatures for the early  
detection of gastric cancer
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Abstract
Autoantibodies against tumor-associated antigens due to their specificity and stability in the 
sera are very attractive biomarkers for the development of non-invasive serological tests for 
the early detection of cancer. In the current study we applied T7 phage display-based SEREX 
technique to identify a representative set of antigens eliciting humoral responses in gastric 
cancer (GC) patients, produced phage-antigen microarrays and exploited them for the survey 
of  autoantibody repertoire  in  patients  with GC and inflammatory  diseases.  We developed 
procedures for data normalization and cutoff determination in order to define sero-positive 
signals  and  rank  them  by  the  signal  intensity  and  frequency  of  reactivity.  To  identify 
autoantibodies with the highest diagnostic value, a 1150-feature microarray was tested with 
sera from 100 patients with GC and 100 cancer-free controls and then the top-ranked 86 
antigens were used for the production of focused array that was tested with an independent 
validation set comprising serum samples from 239 GC patients, 150 peptic ulcer and gastritis 
patients and 213 healthy controls. ROC curve analysis showed that 45-autoantibody signature 
could discriminate GC and healthy controls with AUC of 0.79 (58% sensitivity and 91% 
specificity), GC and peptic ulcer with AUC of 0.76, and GC and gastritis with AUC of 0.64. 
Moreover, it could detect early GC with equal sensitivity than advanced GC. Interestingly, the 
autoantibody  production  did  not  correlate  with  histological  type,  H.  pylori status,  grade, 
localization  and  size  of  the  primary  tumor  while  it  appeared  to  be  associated  with  the 
metastatic disease.  
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Introduction
Despite the overall global decrease in incidence, gastric cancer (GC) with the estimated ~989 600 new 
cases and ~ 738 000 deaths per year remains the fourth most common type of cancer and the second  
most common cause of cancer-related death worldwide (1). The high mortality rate in GC is mostly 
due to its detection at advanced stage (IIIA-IV), when the estimated 5-year survival rate ranges from 4  
to 20% and the median overall  survival  is around 8-12 months.  Only less than 20% of cases are  
detected at an early localized stage when the complete, curative resection is possible and the 5-year  
survival  rate  reaches  75% (2,  3).  The early detection of  GC is  hampered by the lack of  specific 
symptoms before it has spread beyond the original site and the lack of reliable non-invasive screening 
tests.  Currently,  the  diagnosis  is  based  on  endoscopic  examination  followed  by  the  histological 
analysis  of  gastric  biopsy  that  is  an  invasive  technique  not  applicable  for  the  screening  of  
asymptomatic population.  Hence the identification and validation of GC biomarkers that  could be 
detected in body fluids such as plasma, serum or urine and are suitable for the development of non-
invasive  or  minimally  invasive  tests  applicable  for  screening  high-risk  groups  would  represent  a 
significant step towards the reduction of morbidity and mortality caused by GC. 
Autoantibodies  against  tumor-associated  antigens  (TAA)  have  been  detected  by  the  classical  or 
modified SEREX approaches in all cancer types analyzed so far (4, 5) and due to their specificity and 
stability  in  the  sera  they  seem to  be  very  attractive  targets  for  the  development  of  non-invasive  
serological tests for the diagnosis or early detection of cancer. Furthermore, in contrary to the currently  
known  serum  biomarkers  such  as  PSA,  CEA or  CA19-9,  they  are  qualitative  not  quantitative 
biomarkers. However, so far the exploitation of tumor-associated autoantibodies for cancer diagnosis 
has  been hampered by several  factors:  the frequency of  antibodies  against  any individual  TAA is 
generally low, typically ranging from 1 to ~15%; autoantibody repertoire is heterogeneous and to some 
extent  resemble  the  response  to  tissue  damage  by  viral  infections  or  autoimmune  diseases; 
autoantibodies against a number of TAAs, such as CTAG1B, TP53, c-MYC etc. are found in patients  
with different  types of cancer (6-9).  To overcome these limitations,  a number of novel  proteomic 
approaches  including  the  serological  proteome  analysis  (SERPA)  (10),  immunoprecipitation  of 
antigens followed by mass spectrometric analysis (11) and antigen microarrays (12-16) have been 
applied  to  explore  the  autoantibody  profiles  in  cancer  patients  resulting  in  the  discovery  of  
autoantibody signatures with diagnostic significance.
Although the application of the classical  SEREX and proteomics techniques to gastric cancer has 
resulted in the identification of a variety of TAAs (17-20), to our best knowledge, the autoantibody 
repertoire in GC has not been comprehensively characterized and the diagnostic significance of the 
autoantibodies  has not  been evaluated so far.  Moreover,  it  is  not  clear whether  the  production of  
autoantibodies is  related to the metastatic spread,  size of the primary tumor, its  histological  type,  
localization or grade. To address these issues, we applied T7 phage display-based SEREX technique 
(21) to identify a representative set of antigens eliciting humoral responses in GC patients, produced 
phage-displayed antigen microarrays and determined the autoantibody profiles in patients with gastric  
cancer, gastritis, gastric ulcer and healthy individuals and examined the correlation of the autoantibody 
signatures with the clinicopathological features.
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Materials and Methods
Tissue specimens and study population. 
Eleven gastric cancer tissue specimens were macroscopically dissected by a histopathologist during 
surgery at Latvian Oncology Center and stored in RNALater (Applied Biosystems, USA) at -20C 
till processing. Tissue sections were evaluated by an experienced pathologist and the diagnosis was  
established according to standard histopathological criteria. Five of the specimens were diagnosed as 
intestinal, 6 – as diffuse type adenocarcinomas, including 3 signet-ring cell adenocarcinomas; 2 were 
grade II, 5 were grade III and 4 were grade IV cancers. 
Pre-treatment  serum samples  from 232  GC patients  were  collected  at  Latvian  Oncology  Center, 
aliquoted and stored at -80C. Another cohort of 134 GC serum samples was received from Clinic of 
Gastroenterology, Hepatology and Infectious Diseases, Germany. Serum samples from 313 age and 
gender matched cancer-free healthy individuals and 98 patients with gastritis, including 58 patients  
with endoscopically detected atrophy, and 52 patients with gastric ulcer were provided by the Genome 
Database of Latvian Population. Characteristics of the study population are provided in Table 1. 
The tissue and serum specimens were collected after the patients’ informed consent was obtained in  
accordance with the regulations of Committee of Medical Ethics of Latvia and the ethical committee 
of the Otto-von-Guericke University Magdeburg.  
Construction of T7-StrepII tag phage display vectors and cDNA expression libraries. 
A set of three T7-StrepII tag 1-3 vectors was constructed by cloning DNA sequence encoding StrepII  
tag (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) into HindIII and NotI sites of T7Select 10-3b vector DNA 
(Novagen). Three different oligonucleotides carrying one or two nt insertions after the HindIII site 
were used in order to position StrepII tag in the three possible reading frames relatively to N-terminus 
of T7 10B coat protein and cDNA insert. The oligonucleotide duplexes were digested with HindIII and 
NotI,  ligated  into  the  T7Select  10-3b  vector  and  the  ligation  mixture  was  subjected  to  in  vitro 
packaging using T7 Select Packaging extract (Novagen). Three individual phage clones carrying the 
StrepII  tag  in  different  reading  frames  were  selected,  amplified,  vector  DNA was  isolated  using  
phenol/chloroform extraction, ethanol precipitated and digested with EcoRI and HindIII.
The obtained T7-StrepII  tag 1-3 vector set  was used for the construction of gastric cancer cDNA 
expression libraries as described previously (21).  Briefly, total RNA was extracted from 11 tumor 
tissue  specimens  using  TRIzol  reagent  (Invitrogen)  according  to  the  manufacturer’s  instructions. 
mRNA was isolated from 300 µg total RNA pooled from 5 or 6 patients to produce GCP5 and GCP6 
libraries, respectively, using Dynabeads mRNA purification kit (Invitrogen) and converted to cDNA 
using  HindIII  Random  primers  (5’-TTNNNNNN-3’)  (Novagen).  Then  cDNA  was  ligated  to 
directional  EcoRI  and  HindIII  linkers,  digested  with  the  corresponding  restriction  enzymes,  size 
fractioned by gel electrophoresis to isolate fragments of 200 – 1000 bp in length and then ligated into 
pre-digested T7-StrepII tag 1-3 vectors (0.5 µg each). The ligation mixtures were packaged  in vitro 
resulting in GCP5 and GCP6 libraries of 5×106 pfu and 8×106 pfu, respectively. The libraries were 
amplified once in IPTG-induced BLT5615 cells.
Selection of serum-reactive phage clones.
The obtained GCP5 and GCP6 cDNA expression libraries were enriched for ORFs by incubating 
~5×1010pfu  from  each  library  with  40  µl  of  Strep-Tactin  coated  Magnetic  Beads  (IBA GmbH, 
Germany) and the phage particles expressing Strep II tag were purified and eluted according to the 
manufacturer’s instructions. ORF enriched libraries were titrated and used for the biopanning with  
negative and positive selection followed by the immunoscreening with patients’ sera  as  described 
previously  (21).  Briefly,  approximately  3-5×105pfu  from each ORF enriched library  were  at  first 
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incubated with 100 µl of Protein G coated magnetic beads (Pierce), coupled with IgGs from 5 healthy 
individuals and then the unbound phage was incubated overnight with pools of sera from 5 or 6 GC or 
gastritis patients (0.5 µl each). Sera were preabsorbed with BLT5615 and T7 phage lysate coupled to 
CNBr-Sepharose 4B before adding to the phage libraries. A hundred µl of Protein G coated magnetic  
beads were washed twice with blocking solution (5% milk powder in TBS, 0.05% Tween 20), added to 
the phage - serum mixture and incubated for 2 h with agitation. The beads were washed 10 times with 
1 ml TBS, 0.05% Tween and all bound phages were used for the immunoscreening. BLT5615 cells 
grown in LB supplemented with 1×M9 salts, 0.4% glucose, 1mM MgSO4 and carbenicillin (50µg/ml) 
to  OD600=0.5  and  induced  with  IPTG for  30  min  were  infected  with  the  phages  and  plated  on 
LB/carbenicillin agar plates at density ~103pfu per 150 mm plate. After ~2h incubation at 37C when 
the plaques reached ~1mm in diameter, plates were overlaid with Protan nitrocellulose (NC) filters  
(Whatman) and incubated for 1 h at 37C. The filters were blocked with 5% (w/vol) milk powder in 
TBS, 0.05% Tween 20 for 1h, and then incubated overnight with 1:200 diluted patients’ serum that has 
been preabsorbed with E.coli/ phage lysates immobilised on CNBr-Sepharose 4B. The serum-reactive 
clones were detected by incubating the filters with alkaline phosphatase conjugated anti-human IgG, 
Fc specific  secondary  antibody  (Pierce)  and  NBT/BCIP  (Fermentas),  isolated  and  purified  to 
monoclonality. The inserts of serum-reactive phages were amplified by 35-cycle PCR using primers  
flanking  the  insert  and  1  µl  of  phage  solution  as  a  template.  PCR  products  were  purified  and  
sequenced using ABI Prism BigDye Terminator v3.1 cycle sequencing kit and 3130 Genetic Analyser 
(Applied Biosystems). DNA sequences were analysed using BLAST tool at www.ncbi.nlm.nih.gov,  
Translate tool at www.expasy.org and compared against sequences available at Cancer Immunome 
Database (www2.licr.org/CancerImmunomeDB).
Production and processing of phage displayed antigen microarrays.
For the production of 1150-feature antigen microarray, a panel of all different serum-reactive phage 
clones selected from GC cDNA libraries, phage clones previously selected from T7 phage-displayed 
testis, melanoma and prostate cancer cDNA expression libraries and non-recombinant control phages 
was assembled and simultaneously amplified to high titre (~5×108-1×109 pfu/µl) in E. coli BLT 5616 
cells  using  96  well  culture  plates  (Whatman).  The  lysates  were  clarified  by  centrifugation,  
supplemented with 5% glycerol  and 0.1%NaN3 and arrayed in  quadruplicates onto nitrocellulose-
coated 2-pad FAST slides (Whatman) using a QArray Mini microarrayer (Genetix). The microarray 
slides were blocked with 5% (w/vol) milk powder in TBS, 0.05% Tween 20, incubated with 0.9 ml of  
1:200 diluted patients’ sera that were preabsorbed with 15 µl of UV-inactivated E.coli- phage lysates, 
washed 4 times in TBS, 0.5% Tween 20 for 15 min, and then incubated with monoclonal anti-T7 tail 
fiber antibody (Novagen). After 3 washes in TBS, 0.5% Tween 20, the microarrays were incubated 
with Cy5 labelled goat  anti-human IgG antibody (1:1500)  and Cy3 labelled goat  anti-mouse IgG 
antibody (1:3000) (Jackson ImmunoResearch) for 1 h, then washed thrice in TBS, 0.5% Tween 20,  
rinsed with distilled water and dried by centrifugation. A reference serum was included in each series  
of experiments. The arrays were scanned at 10 µm resolution in PowerScanner (Tecan) with 532 and 
635 nm lasers,  the results were recorded as TIFF files and the data were extracted using GenePix  
software. The obtained data were further analyzed using an ad hoc program composed in R language. 
For the production of 96-feature antigen microarray, the selected phage clones were amplified from the 
low-titre stocks as described before, quality-controlled by PCR and spotted onto 16-pad FAST slides 
in duplicates and the arrays were processed as described above. 
Microarray data processing and statistical analysis.
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For  each  spot  the  mean  Cy5  and  Cy3  signals  were  background  subtracted,  averaged  between  
replicates, and the Cy5/Cy3 ratios were calculated for each antigen. Spots that did not pass the quality 
criteria  (morphologically  heterogeneous spots  and spots  that  differed by  more than 50% between 
replicates)  were  excluded  from the  analysis.  A two-step  normalization  strategy  was  used  for  the 
fluorescent  signal  ratios  in  order  to  eliminate  variations  introduced  by  the  custom production  of 
microarrays and variable background intensities of different sera. At first,  the values in each slide  
(each  serum)  were  normalized  by  the  median  of  the  middle  80% of  all  measurements  for  each 
fluorescent  channel  separately.  Then  the  distribution  of  data  across  an  array  was  centered  by 
equalizing  the  standard  deviation  of  the  middle  80%  of  values  to  1.  Next,  for  the  inter-slide 
normalization, the Cy5 and Cy3 signal intensities for each spot were divided by the median of the  
middle 80% of the values for this spot in slides within one batch and the distribution was centered 
across slides in the batch. The highest and lowest 10% of the values were excluded from the SD 
calculation in order not to dismiss the outliers that may represent serum-positive antigens. 
The cutoff value (T) for each antigen was calculated as follows: 
, where IHD is the signal intensities in healthy controls. Then the antigens were ranked, taking into  
account the signal intensity and frequency of reactivity with GC patient sera compared to healthy 
donor sera, using the following formula:
 
Finally, a score for each serum was calculated as follows: 
. 
The  non-parametric  Mann-Whitney  U  test  was  used  to  compare  the  serum  scores  between  two 
independent groups of samples. The receiver operating characteristic (ROC) curve was constructed 
and the area under the curve (AUC) was calculated to evaluate the diagnostic performance of the  
serum scores. Leave one-out cross validation (LOOCV) as described by Laxman B et al, 2008 was 
used to validate the biomarker models to eliminate overestimated values (22). To define cutoff points  
on the ROC curves with the maximal sum of sensitivity and specificity Minimal misclassification cost  
term (MCT) approach (23) was used as follows: 
, where the cost(FN)/cost(FP) was set at 0.5. 
73
Results and Discussion
Discovery of gastric cancer antigens.
In order to identify a representative set of antigens eliciting humoral immune responses in GC 
patients,  two  phage-displayed  cDNA expression  libraries,  called  GCP5  and  GCP6,  were 
constructed from pools of total RNA isolated from 5 intestinal type and 6 diffuse type gastric 
adenocarcinoma specimens, respectively, and the serum-reactive phage clones were selected 
with sera pooled from 27 GC patients. The workflow of this study is shown in Figure 1. A 
modified T7 Select 10-3b phage display system carrying the Strep II tag was used for the 
construction of the expression libraries. In the standard version, cDNAs are expressed as C-
terminal fusion proteins with the phage coat protein 10B resulting in the display of a large 
proportion of out-of-frame peptides. In fact, we and others have previously observed that only 
~2 to 10% of the phage clones selected from T7 phage display libraries expressed proteins in 
their natural reading frame, while the remaining clones contained DNA fragments translated 
in non-natural reading frames that most likely represent mimotopes (13, 21). To increase the 
proportion of in-frame antigens, we constructed a set of three T7-StrepII tag vectors that allow 
selecting the phages displaying in-frame antigens by ORF enrichment step using Strep-Tactin 
coated  magnetic  beads  prior  to  the  selection  of  serum-reactive  clones.  After  the  negative 
selection step with healthy donors’ IgGs, both GC cDNA expression libraries were screened 
with  pooled  autologous  sera  and  with  3  pools  of  allogeneic  sera  (5  diffuse  type  and  5 
intestinal type adenocarcinomas of various stages and 6 stage I and IIA adenocarcinomas of 
various  types)  (Table  1)  by  performing  a  single  round  of  biopanning  followed  by 
immunoscreening of the enriched libraries. This resulted in the identification of 316 different 
serum-reactive phage clones. Sixty eight of them (21.5%) encoded proteins in their natural 
reading frames thus showing that the application of T7-StrepII tag vector system  substantially 
increased the proportion of the identified in-frame antigens. Among the in-frame antigens 
were 4 known cancer-testis (CT) antigens (CTAG1B/NY-ESO1, CTAG2/LAGE-1, DDX53, 
HORMAD1),  9  antigens  that  have  been  previously  identified  by  applying  conventional 
SEREX to  various  tumour  types  (NOL8,  UBR2,  SC65,  KTN1,  RPLP1,  TPM3, ZNF282, 
HSPA4 and EEF1A1), a number of ribosomal proteins and heat-shock proteins known to elicit 
humoral response both, in cancer patients and patients with autoimmune diseases, but the rest 
of the antigens have not been previously implicated in autoimmune responses. The remaining 
248 serum-reactive clones contained cDNAs fused to 10B in a different reading frame, 5’ or 
3’ UTRs,  ribosomal RNA genes  or  mitochondrial  DNA, thus  expressing  4 to  80 aa  long 
peptides that likely represent mimotopes. The nature of the antigens they represent is not 
known as they may mimic protein as well as non-protein antigens of cancer or normal cells or  
various pathogens.
Identification of autoantibody signature with the diagnostic significance.
A panel  of  all  316  serum-reactive  phage  clones  identified  by  screening  of  GC  cDNA 
expression  libraries,  70  non-recombinant  phage  clones  and  764  phage  clones  previously 
74
selected from T7 phage-displayed testis,  melanoma and prostate  cancer  cDNA expression 
libraries (21, 24) was assembled and used for the production of 1150-feature phage-antigen 
microarray.  The  microarray  comprised  46  antigens  representing  16  CT  antigen  families 
(CTAG1B/CTAG2,  CTAGE,  MAGE-A,  MAGE-C,  SSX,  GAGE,  HORMAD,  DDX53, 
CSAG, PAGE, BAGE, SPANX, CT45,  THEG, LDHC and SPAG), 152 in-frame antigens 
including known tumor-associated antigens such as ANXA11 and TYR, autoantigens such as 
AKAP12  and  LMOD1  and  previously  uncharacterized  antigens,  and  882  out-of-frame 
peptides.  In  order  to  define  autoantibodies  with  a  potential  diagnostic  significance,  the 
microarray was tested with sera from 100 patients with gastric cancer of various histological 
types  and stages  and 100 age and gender  matched healthy individuals as  the training set 
(Table 1). After excluding low-quality spots and correcting for the variations in the phage 
quantity  and  differences  across  the  print  runs,  and  allowing  inter-slide  (inter-serum) 
comparisons by the two-step normalization, an individual cutoff discriminating between sero-
positive and negative samples was calculated for each antigen. The cutoff was experimentally 
validated  by  plaque  assay  for  3  antigens  –  CTAG1B,  HORMAD1 and  SPAG17 using  3 
positive and 3 negative sera according to the microarray data (data not shown). In total, 888 
antigens reacted with at least one of these sera, however many of them reacted at a similar 
frequency with cancer patients’ and healthy donors’ sera. In order to select a panel of antigens 
eliciting the antibody response that is highly specific to cancer patients, the antigens were 
ranked considering the signal intensity above the cutoff and higher frequency of reactivity 
with cancer patients’ sera than with healthy individuals’ sera as described in  Materials and 
Methods. Three hundred sixty antigens reacted preferentially with cancer patients’ sera thus 
receiving  a  positive  rating,  and  therefore  were  considered  to  have  a  potential  diagnostic 
significance.  Next,  the “serum score” was calculated for  each serum by summing up the 
signal intensities above the cutoff for all the significant antigens. It ranged from 0 to 1400 
(mean 107)  in  GC patients  and from 0 to  150 in  healthy  individuals  (mean 11)  and the 
difference  was  statistically  highly  significant  (P=9.5×10-26)  (Fig.  2A).  The  diagnostic 
performance of the serum score was evaluated by the ROC curve analysis and yielded AUC of 
0.85 (95% CI 0.81-0.88, P=9.5×10-26), sensitivity (Sn) of 57% and specificity (Sp) of 92% at 
the  cutoff  point  35.3  (Fig.  2B).  However,  this  biomarker  set  included antigens  with  low 
diagnostic value (reacting with 1-2% of cancer patients’ sera or signal intensities less than 2 
fold above the cutoff); moreover, the development of clinically applicable biomarker assay 
based on 360 antigens would be impractical, therefore we next selected a set of 86 top-ranked 
antigens with the highest specificity. This set had AUC of 0.81 (95% CI 0.78-0.84, P=1.9×10-
23), sensitivity of 69% and specificity of 89% at the cutoff point 3.4 (Fig. 2B). 
Diagnostic performance of the autoantibody signature.
The phage clones encoding the selected 86 antigens, along with 10 non-recombinant phage 
clones,  were amplified and used for the production of 96-feature phage-antigen array.  To 
evaluate the reproducibility between 1150-feature and 96-feature arrays, it  was tested with 
randomly selected 50 GC patients’ and 20 healthy donors’ sera previously used in the training 
set. It showed 89% concordance in detecting sero-positive signals, with an average CV of 
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~13%,  which  is  an  acceptable  inter-assay  variability  for  immunoassays.  To  establish  the 
diagnostic  value  of  the  selected  antigens,  the  array  was  tested  for  the  reactivity  with  an 
independent  validation  set  including  sera  from 239 GC patients  at  various  stages  and of 
various histological types and 213 healthy individuals with no history of cancer (Table 1). The 
ranking of antigens was performed as described above and it showed that all of these antigens 
scored above zero. The mean serum score calculated on the basis of these antigens differed by 
more  than  43-fold  between  GC patients  and  healthy  donors  and  could  discriminate  GC 
patients and healthy donors with AUC of 0.76 (95% CI 0.74-0.79, P= 6×10-25, Sn 49%, Sp 
93%) (Fig. 2C). Next, we made an attempt to further reduce the number of biomarkers by 
backward  elimination  approach  and  found  that  the  minimal  set  of  antigens  retaining 
comparative sensitivity comprised 45 antigens yielding AUC of 0.79 (95% CI 0.76-0.81,P= 
6×10-31, Sn 58%, Sp 91% at cutoff 2.45) (Table 2, Supplementary Table S1, patent pending).  
To  validate  the  performance  of  45-autoantibody  signature,  leave-one-out  cross  validation 
(LOOCV) was performed and it yielded AUC of 0.75 (95% CI 0.72-0.78, P=1.5×10-24, Sn 
39%, Sp 97% at cutoff 4.92) (Fig. 2C)
In  order  to  evaluate  the  diagnostic  performance  of  the  autoantibody  signature  in  the 
population in which the assay could be employed – e.g. patients with various inflammatory 
gastric disorders, the array was tested with sera from 52 patients with peptic ulcer and 98 
patients with acute or chronic gastritis and all the calculations were performed as described 
above. The mean serum score in ulcer group was 1.3 that does not significantly differ from 
that  in  healthy  individuals  (Fig.  2D)  and  the  ROC  curve  analysis  showed  that  the  45-
autoantibody signature could discriminate between the GC and ulcer with AUC 0.76 (Table 2, 
Fig. 2E). This shows that the identified autoantibody signature does not significantly overlap 
with B cell response to cancer non-related lesions of gastric mucosa. At the same time, the 
serum scores in gastritis patients, although still significantly lower than in GC patients, were 
higher  than  in  patients  with  ulcer  and healthy  controls  (Fig.  2D)  and  could  discriminate 
between GC with AUC 0.64 (Table 2, Fig. 2E). As shown in Figure 2F, a specific pattern of 
reactivity was shared between GC and gastritis that was absent in patients with ulcer and 
healthy controls.  Among these antigens was PRKACA that previously has been shown to 
induce autoantibody responses in various cancers (25) and NOL8 that has been detected by 
SEREX in lung cancer, while the others are out-of-frame peptides whose nature is unknown. 
It is likely that these responses are triggered by cancer non-related inflammation and thus 
have no relevance for diagnosis. Alternatively, taking into account that gastric atrophy is a 
well  recognized precancerous condition (26), it  could be possible that among the gastritis 
patients were clinically undetectable GC cases, hence these could be cancer-specific antigens 
recognized at very early stages of cancer. 
What are the antigens with the highest diagnostic value? 
Five of the top 10 ranked antigens are known CT antigens but the others most likely are  
mimotopes  of  antigens  whose  nature  is  unknown (Table  3).  Spontaneous  B cell  immune 
responses against CTAG2 and CTAG1B have been observed in patients with various types of 
cancer,  including  GC,  while  anti-DDX53  antibodies  have  been  detected  in  patients  with 
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melanoma, colon and endometrial cancers and anti-MAGEA3 and MAGEC1 antibodies – in 
melanoma patients (27-29). Their immunogenicity is thought to be related to the expression 
pattern:  they  are  expressed  in  a  wide  range  of  cancers,  but  normally  their  expression  is 
restricted to immuno-privileged tissues such as testis, fetal ovary and placenta. Hence they 
become exposed to the immune system only when expressed by tumors, therefore the immune 
response  against  these antigens  could  serve  as  a  very specific  indicator  of  cancer,  but  is 
unlikely to discriminate between different types of cancer. The fact that autoantibodies against 
these  antigens  are  very  rarely  detected  in  cancer-free  controls  (in  the  current  study  we 
detected anti-CTAG2/CTAG1B, DDX53 and MAGEA3 antibodies in 3 controls: two of them 
were  diagnosed  with  melanoma  and  lung  cancer  8  and  5  months  after  the  blood  draw, 
respectively, and were excluded from the analysis but no follow-up information was available 
for the third one),  seems to argue against the cancer immunoediting concept proposed by 
Schreiber RD et al (30). However, it has been demonstrated that the CT antigen expression 
tends to correlate with an advanced stage and is higher in metastatic than primary tumors (28). 
Thus  it  could  be  possible  that  tumors  start  to  express  CT antigens  only  after  they  have 
undergone elimination and equilibrium stages and their  expression represents a feature of 
immunologically sculpted tumors. Alternatively, it has been demonstrated that B cells have a 
key role in the initiation of tumor-promoting inflammation (31), hence it could be possible 
that the appearance of tumor-specific antibodies marks the point-of-no-return in the cancer 
immunoediting process. In line with this, Willimsky G et al (32) has demonstrated that the 
initiation of B cell response to a tumor antigen coincides with the development of tumor-
specific tolerance and cytotoxic T cell unresponsiveness. 
The frequency of cancer-specific autoantibodies in GC patients ranges from 16.3 to 0.84% 
that is relatively low in comparison with the frequencies reported in other cancer types, such 
as ovarian, lung or breast cancer, where, for example, anti-p53 antibodies may reach 45.5%, 
anti-cyclin B1 antibodies - 34.8% and anti-Her2/neu antibodies – 26.6%, respectively (33). 
This suggests that either GC is generally less immunogenic than the other cancers or the 
autoantibody repertoire is more heterogeneous that is supported by the large number of rare 
autoantibodies identified in this study. Although these low frequency antibodies still may have 
a diagnostic value, the validation by standard statistical analysis is difficult, as this requires 
very large sample cohorts.
Does the autoantibody production correlate with clinicopathological features? 
The questions, when during the tumor progression the autoantibodies appear and what are the 
pathological stimuli triggering this response, are of paramount importance, when considering 
them as diagnostic or prognostic biomarkers. To address these issues the serum scores and the 
frequency of individual autoantibodies was correlated with clinical and pathological features 
of the GC patients. The serum score and the sensitivity for the detection of stage I patients 
was not significantly lower than that for patients with more advanced disease (stage II-IV) 
(Fig. 3A, Table 2-3) thus demonstrating the relevance of the identified autoantibody signature 
for  early  detection  of  GC.  No  significant  correlation  between  the  serum  score  and  the 
histological type,  H. pylori status, tumor grade, patient age and gender was observed (Table 
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2). In regard to tumor localization, a set of antigens that were recognized by sera from patients 
with distal but not proximal GC was identified (Fig. 3B), however the overall serum scores 
did not significantly differ  between these groups.  Most importantly and unexpectedly,  the 
serum score did not correlate with the size of primary tumor showing that the tumor burden 
by itself is not crucial for triggering the antibody response. Instead, we found that the serum 
scores were significantly higher in patients with distant metastases than with non-metastatic 
disease, while the metastatic spread limited to the regional lymph nodes did not affect the 
autoantibody production (Fig. 3C). However, it is not entirely clear whether this is due to the 
predominant expression of the antigens on metastatic tumors or the metastatic spread by itself 
stimulates the B cell response. 
Taken together, we have developed a novel approach for the analysis of antigen microarray 
data and applied it for the survey of the autoantibody repertoire in GC. A similar strategy has 
been taken by Gnjatic S et al (34, 35) and, in contrary to t-tests, regression analysis, pattern-
recognition approaches and the artificial neural network-based approaches so far used in the 
antigen microarray data analysis (36, 37), it is aimed at defining clearly sero-positive signals 
and analyzing them quantitatively, rather than identifying small but consistent differences in 
the signal intensity with unknown biological significance. This resulted in the identification of 
45- autoantibody signature that could discriminate between GC and healthy control sera with 
74.5% accuracy. It has substantially higher specificity than the currently known GC serum 
markers such as CA 72-4, CA19-9 and CEA (38, 39). Strikingly, stage I GC could be detected 
with a similar sensitivity to advanced GC suggesting that this autoantibody signature could be 
exploited for the early detection of GC. However, the sensitivity of the model is not sufficient 
for the development of screening tests for an asymptomatic population and it remains unclear 
whether this is due to the low immunogenicity of GC or high complexity of autoantibody 
repertoire in GC, therefore the next task is to explore the autoantibody repertoire in those GC 
patients that were negative for the identified autoantibody signature. Furthermore, although 
this study provided some insight into the pathological processes associated with the cancer-
specific autoantibody production, the functional role of autoantibodies in the development 
and/or progression of cancer and anti-tumor immune response is still elusive and it would be 
of great interest to explore their predictive and prognostic significance.
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Figures
Figure 1. The workflow of antigen discovery, the production of antigen microarrays and the 
selection of the autoantibody signature with diagnostic relevance.
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Figure  2. The  identification  of  autoantibody  signature  with  diagnostic  relevance  and  the 
evaluation of its diagnostic performance. (A) box plot showing serum scores based on the 
reactivity against the top 360 antigens in the training set consisting of serum samples from 
100 GC patients and 100 healthy controls (HD). Boxes represent interquartile range - distance 
between the 25th and 75th percentiles; whiskers represent most extreme data point, which is no 
more  than  1.5  times  the  interquartile  range  from  the  box  and  dots  represent  individual 
samples. Dotted line represents the cutoff determined by minimal misclassification cost term 
approach. Statistical significance was calculated using Mann-Whitney U test. (B) ROC curves 
showing the diagnostic  performance of the 360-autoantibody and the top 86-autoantibody 
signatures in the training sample set. (C) ROC curves showing the diagnostic performance 
(discrimination between GC and HD) of the 86-autoantibody and 45-autoantibody signatures 
and their LOOCV in the independent validation set consisting of serum samples from 239 GC 
patients and 213 healthy controls (HD). (D) box plot showing the serum scores based on 45-
autoantibody signature in the validation sample set and patients with peptic ulcer and gastritis. 
(E)  ROC curves  showing  the  discrimination  between  patients  with  GC,  peptic  ulcer  and 
gastritis using the 45-autoantibody signature. (F) dot plot showing reactivity pattern shared 
between patients with GC and gastritis. Statistical significance between groups combing HD 
and ulcer, and GC and gastrtis was calculated using Mann-Whitney U test.
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Figure 3.  The serum reactivity in various subgroups of patients. (A) box plot showing the 
serum scores based on 45-autoantibody signature in patients with various stages of GC and 
HDs. (B) dot plot showing reactivity pattern distinguishing distal and proximal GC. Statistical 
significance was calculated using Mann-Whitney  U  test.  (C) box plot showing the serum 
scores based on 45-autoantibody signature in GC patients with or without distal metastases 
(Tx,Nx,M0 vs Tx,Nx,M1).  
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 4. DISCUSSION
The exploitation of autoantibodies as diagnostic, prognostic or predictive biomarkers of 
cancer for the clinical applications so far is limited by a number of biological factors: 
• The frequency of antibodies against any individual antigen in generally relatively low, 
typically ranging from 1 to ~30% (104-106). 
• Autoantibody repertoires,  even  in  patients  with  the  same type  of  cancer,  are  very 
heterogeneous.
• Autoantibodies against a number of TAAs, such as p53, cyclin B1, c-MYC etc, have 
been  found in  patients  with  different  cancers  (80),  thus  they  have  a  limited  potential  to 
discriminate between different types of cancers. 
• The  repertoire  of  cancer-associated  autoantibodies  partially  overlaps  with  that  in 
inflammatory, autoimmune and viral disorders and partially resemble the immune response 
induced by tissue damage  (9,107,108), therefore the validation of an autoantibody as truly 
cancer-associated  antibody  would  require  testing  large  cohorts  of  patients  with  various 
disorders.  
• The  role  of  autoantibodies  in  anti-tumour  immune  response  and  their  clinical 
significance is still elusive and controversial.
Protein microarray technology is a valuable tool for exploring autoantibody profiles in 
human sera and defining the repertoire of the humoral immune response to cancer  (109). 
However, the development of such high-throughput technologies raise volume of the obtained 
data that bring the original matters up and demand more subtle and complex optimization of 
the data analysis. The original paper I describes the development of phage-displayed antigen 
microarray  (PhD-AM) technology  and  the  comparison  of  suitability  of  T7  and   phage 
display systems for the production of microarrays. 
 4.1 . Reproducibility and sensitivity of PhD-MA technique
The protocol for production of PhD-MA was developed by addressing the following 
issues: choice of slide surface chemistry, choice of method for the amplification of phages, 
antibody  dilutions,  serum  preabsorbtion,  printing  conditions  and  data  acquisition.  The 
technique  showed  a  variability  that  is  generally  acceptable  for  the  immunoassays.  The 
sensitivity  of  PhD-MA is  comparable  with  plaque  immunoscreening  that  is  the  basis  of 
SEREX technique and underlies the identification of the majority of currently known tumour 
antigens  eliciting  humoural  immune  response.  Although  the  immunoscreening  is  not  a 
quantitative technique,  it  is perfectly suitable for discrimination between sero-positive and 
sero-negative signals. The PhD-MA technique maintains the capacity to detected the presence 
of specific autoantibodies qualitatively and in addition it provides the opportunity to quantify 
the sero-positive signals. The development of this technique allows us to address a variety of 
scientifically  and  clinically  relevant  questions,  such  as  (i)  do  the  tumour-associated 
autoantibodies have a diagnostic relevance? (ii) When during the cancer development they 
appear? (iii) Is the production of autoantibodies related to the metastatic spread, size of the 
primary tumor, its histological type, localization or grade? (iv)  Do they have a prognostic 
relevance? (v) What do they tell about the status of patient’s immune system and are they 
predictive of response to immunotherapy?
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 4.2 . Data processing and normalisation
A new  normalization  approach has  been elaborated for  our  studies  described in  the 
original papers II, III and IV.
The  systematic  or  random  variability  of  multiple  sources  are  possible  during  the 
manufacturing, processing and scanning of microarrays. It can arise from technical sources: 
the  heterogeneity  of  the  surface  of  the  slide,  the  differences  between  printing  groups, 
difference in sample preparation, fluorescence of labels, intensity-dependent variation in two 
fluorescent dyes, total serum activity and variation of amount of biological material in printed 
spots.  The  possibility  to  allocate  close  to  pure  sample  when  we  can  guarantee  identical 
quantity of an operating part in all spots of the array not always there. To remove technical 
variation we should apply normalization to obtained data. 
Figure  4. DNA microarray  and  PhD-AM images  and  histograms showing the  data 
distribution.
In  comparison  to  DNA microarray  protein  microarrays  are  more  variable  by  the 
complexity  of  proteomic.  The  functional  protein  microarray  despite  its  methodological 
similarity  does  not always tolerate  the approaches  developed for  DNA microarray due to 
additional noise sources (92) - greater chemical diversity of the protein molecules and larger 
amplitude of the specificity in interaction with the samples. This trend is reinforced by PhD-
AM, when total  lysate contained the protein of interest in a variable proportion to the total 
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amount of protein applied to the slide. Since the exact content of spots in DNA microarray is 
known the elimination of spatial effects always in focus of the within array normalization of 
DNA data.  Some of these effects are excluded at the stage of background removal and the 
procedure should be preserved for the  PhD-AM. The classic methods of normalization of 
DNA microarray data, such as LOWESS and it most modern variation OLIN, make it by 
aligning on certain areas.
The following methods for DNA microarrays classically applied for normalization were 
tested in our study: quantile and global normalizations with or without OLIN. OLIN as well 
as LOWESS approach, implies a near equal number up- and down- regulated signals on all 
amplitude of intensities. It is not correct for data with sectors of low density of signals. OLIN 
and LOWESS clearly show the tendency to loose the same qualitative signals on our dataset. 
In contrast to DNA case, when these methods provide the reasonable solution, in  PhD-AM, 
where biological variance between printed spots is more higher and in most cases exceed 
residual spatial effects after background subtraction. Usually global and especially quantile 
normalization affect very strongly on outliers, which as will be shown below, is an extremely 
important part of data, bringing them closer to the total normal distribution.
The home-made slides used in the study were printed by portions – print batches due to 
technical reasons. The “batch effect” issue, when the data from multiple separately produced 
slides is combined, represents a significant challenge for more monotonous DNA microarray 
as well (110). Our dataset shows that batch effect is the main reason of systematic variability. 
Thus, the one of the most difficult type of microarray from the standpoint of normalization 
was used in our study. 
The adopted variant of global normalization and correction by batch mean-centering 
(111) was developed by us and used for the within array and inter array normalization. It is 
more careful to the outliers and based on specific knowledge about our dataset. There are no 
more than 20% coverage of positive serum signals for each of the antigens, and no more than 
20% of the antigens react with a single serum, as can be seen by evaluating the preliminary 
results (Fig. 4). Each microarray batch was hybridized by mixed group of serum (usually 
about 30% is from healthy donors and other serums from patients with different types of 
cancer), so we can be sure that no more 10% of signals for each antigen can be positive. One 
of ways to achieve acceptable reproducibility due spatial effects in DNA microarray is simply 
increasing the number of local control spots (112). In our proposed method the 80% of spots 
were used as base group for normalization.
 4.3 . Methods of data analysis
The  identification  of  statistically  significant  changes  in  the  majority  of  microarray 
studies  is  based  on  the  classical  methods  such  as  t-test,  ANOVA,  Bayesian  networks  or 
relatively new computationally expensive machine learning algorithms: K nearest neighbor, 
Linear  Discriminant  analysis,  Artificial  Neuron  Networks  and  Support  Vector  Machines 
(SVM)  (113,114). The latest  is  one of most powerful modern classifiers,  which works by 
separating virtual high dimensional space by optimal hyper plane that minimizes boundaries 
between two classes.
Support Vector Machines. We apply SVM with standard RBF kernel and proposed in 
our  study  topological  rank-based  kernel  to  our  PhD-AM data  from patients  with  gastric 
cancer, melanoma, prostate, gastrointestinal inflammatory diseases and healthy individuals as 
it  described  in  original  papers  II. Preliminary  analysis  showed  no  statistically  significant 
difference of means for majority antigens. For such the dataset clearly seen one of weakness 
of  standard  SVM  kernels,  as  well  as  many  other  analytical  methods,  named  “curse  of 
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dimensionality”.  The  common  point  of  these  problem  for  methods  that  requires  statistic 
significance  is  that  when  the  dimensionality  increases,  the  volume  of  the  virtual  high 
dimensional space increases so fast that the available data becomes sparse. 
Ranking-based topological  kernel. Our  improvement  to  conventional  linear  kernel 
model of SVM can be characterized as transition from quantitative to qualitative approach, 
when data  during preprocessing  were  converted  from virtually  euclidean space  to  ranked 
array of antigens for each sample thus mitigates possible overfitting effects.  Our proposed 
SVM approach include Multiple Kernel Learning extension which can improve performance 
in comparison to single kernel algorithm. Each basis kernel may either use the full set of 
attributes or subsets of it.
Ranking-based topological kernel significantly increase classification rate in compare to 
RBF  kernel  and  have  good  generalization  on  unseen  data  as  it  had  been  showed  by 
verification sets. Unfortunately it have same disadvantages that is important for development 
of diagnostic or prognostic signatures of autoantibody.
Our proposed kernel like conventional SVM classifier, as well as classic statistical tests, 
like  t-test  or  ANOVA based on comparison of  mean/median  and  proposed distribution  is 
looking for significant changes in the majority of samples belonging to two classes being 
compared even if this changes are very small in absolute scale  (115).  This approach is not 
applicable for study, where is preferred biomarkers suitable for diagnostic.
Cutoff  and  ranking  based  procedure. An  approach  more  oriented  on  serological 
reactivity of autoantibodies has been developed for our study described in original paper IV. 
We suggested that the serum-reactive signals of cancer patients consist from two groups: first 
group  coincides  with  serum-reactive  signals  of  healthy  patients  and  second  small  group 
received from patients who have the highly reactive specific antibodies to a particular antigen. 
The data of last patient group can be interpreted as the outliers relatively to the  data from 
healthy individuals and the rest of the cancer patients. Outliers are defined as observations 
that are far from main part of data. In methods conventionally used for analysis of microarray 
data,  the  outliers  often  are  treated  as  low-quality  data  and  most  of  the  methods  offer 
instruments to remove outliers or replace with acceptable data within the main distribution 
(116,117). We stress that such outliers as most important part of our dataset (Fig. 5). 
The best  threshold  or  “cutoff”  for  distinguish between positive  and negative  results 
typically accepted in practice of biological statistic is mean or median of the negative control 
group  plus  two  or  three  times  the  standard  deviation.  This  coefficient  comes  from  the 
assumption that the data have a distribution close to the Poisson distribution. In this case, 
about 95.45% of the values lie within 2 standard deviations. Nearly all (99.73%) of the values 
lie within 3 standard deviations. We tested our approach with cut-off at coefficient equal to 2, 
3, 4 and 5. Threshold at is median of the negative control group plus three times the standard 
deviation  show  the  smallest  error  in  classification  with  Leave-One-Out  cross-validation 
method.
We  developed  a  model  that  have  significant  advantages  for  biologists  by  clear 
demonstration of most powerful antigens in comparison to SVM that is “black box” system. It 
gives the classification results and does not provide reasons of classification. Our model based 
on rank assigned to each antigen accordingly to intensities of positive signals within cancer 
patients compared to healthy donors. Then scoring of each serum can be calculated. Formula 
described in section Materials and Methods.
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Figure 5. Autoantibody responses in sera of patients with gastric cancer and healthy donors.
Our tests on data of described in original paper IV demonstrate importance of cut-off for 
SVM  with  standard  and  improved  Ranking-based  topological  kernels.  Performance  of 
classification  were  validated  with  Leave-One-Out  method  and  show  12%  difference  in 
performance  on  data  before(AUC 71%) and  after(AUC 83%)  cutoff  applied.  Thus  stress 
importance of use of serologically defined cutoff.
 4.4 . Analyses of sperm-associated antigens
Among the antigens previously identified by PhD-SEREX approach was a members of 
the sperm associated antigen (SPAG) group - SPAG8, for which a melanoma associated serum 
response  was  demonstrated  in  our  initial  microarray-mediated  autoantibody  profiling  of 
cancer patients’ sera (see original paper I). SPAG group antigens share a common expression 
pattern in male germ cells and infertility-related autoimmunity, as well as recent indications of 
oncogenic  potential  (118-129).  The  germ-cell  associated  expression,  immunogenicity  and 
oncogenicity are the characteristics of a typical cancer-testis (CT) antigen with a potential 
application  in  tumour  immunotherapy  (130).  Hence  SPAG8 together  with  the  rest  of  the 
members of the SPAG group were chosen for in depth analyses with a goal to determine their  
potential  use  as  novel  tumour  immunotherapy  targets,  including  mRNA  and  protein 
expression analyses in various normal and tumour tissues and the evaluation of the frequency 
of  spontaneous  humoral  immune  response  in  cancer  patients  against  these  antigens.  The 
elaborated PhD-AM production approach was applied to generate a focused SPAG group and 
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CT antigen microarray on 16-pad nitrocelullose slides by printing the recombinant phages in 
triplicate. It was used for the screening of 39 breast cancer, 33 colon cancer, 24 lung cancer, 
28 thyroid cancer, 28 leukemia, 172 gastric cancer, 52 prostate cancer and 163 melanoma 
patients’ sera. The elaborated 2-step normalization was applied to the obtained data and the 
seropositivity cutoff  was set as four standard deviations above the average signal intensity of 
70 non-recombinant phage clones. 
Cancer-associated  serum response  was demonstrated  for  five of  the  analysed SPAG 
antigens  (SPAG1,  SPAG6,  SPAG8 and  SPAG17-A1),  whose  mRNA expression  was  also 
elevated in various tumour tissues. All of these were expressed predominantly in testis among 
normal tissues except for SPAG1 as its mRNA was highly expressed also in normal colon, and 
ascribe these as novel CT antigens with potential applications in tumour immunotherapy or 
serodiagnosis.
This  study  showed  that  the  established  autoantibody  screening  approach  can  be 
successfully utilized to analyze humoral immune responses against many cancer types and 
yields  reliable  and  reproducible  results  as  clearly  demonstrated  by  a  further  focused 
microarray generated to validate the specific autoantibody response against SPAG17 novel 
splice variant SPAG17-A1 (see original paper 3). 
 4.5 . Identification of autoantibody signature for diagnosis of  
gastric cancer
The early detection of gastric cancer (GC) is hampered by the lack of specific symptoms 
before it has spread beyond the original site and the lack of reliable non-invasive screening 
tests. Detection at late stages leads to application of more radical treatment possessing serious 
side effects, much lower level of survival rate (less than 20% in 5 years period, in comparison 
with 75% at detection at early stages)(131,132). Aim of the study described in original paper 
IV  is  to  discover  autoantibody  signatures  with  diagnostic  significance  and  examine  the 
correlation of the autoantibody signatures with the clinicopathological features. We applied 
T7 phage display-based SEREX technique to identify a representative set of antigens eliciting 
humoral responses in GC patients. For the production of 1150-feature antigen microarray, a 
panel of all different serum-reactive phage clones selected from GC cDNA libraries, phage 
clones  previously  selected from T7 phage-displayed testis,  melanoma and prostate  cancer 
cDNA expression libraries and non-recombinant control phages was assembled and arrayed 
onto FAST slides. The microarray was tested with sera from 100 patients with GC and 100 
cancer-free controls.  In total, 888 antigens reacted with at least one of tested sera. Many of 
them reacted at a similar frequency with cancer patients’ and healthy donors’ sera. 
The  cutoff  selection  approach  described  in  the  section  Cutoff  and  ranking  based  
procedure was  applied  and  experimentally  validated  by  plaque  assay  for  3  antigens  – 
CTAG1B, HORMAD1 and SPAG17 using 3 positive and 3 negative sera according to the 
microarray data.
The top-ranked 86 antigens were used for the production of focused array. Test of the 
reproducibility of the signals made for randomly selected 50 patients with gastric cancer and 
20 healthy donors on 1150-feature and 96-feature arrays showed with an average coefficient 
of variability 13%. It is an acceptable level for immunoasseys (103).
Focused array was tested with an independent validation set comprising serum samples 
from 239 GC patients, 150 peptic ulcer and gastritis patients and 213 healthy controls. 
The mean serum score differed between GC patients and healthy donors by more than 
43-fold. The 86 antigen set could discriminate GC patients and healthy donors with AUC of 
0.76 (95% CI 0.74-0.79, P= 6×10-25, Sn 49%, Sp 93%).
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To reduce the number of biomarkers we applied backward elimination approach and 
found the minimal set of 45 antigens that keeps the same level of sensitivity. ROC curve 
analysis showed that 45-autoantibody signature could discriminate GC and healthy controls 
with AUC of 0.79 (95% CI 0.76-0.81,P= 6×10-31, Sn 58%, Sp 91% at cutoff 2.45), GC and 
peptic ulcer with AUC of 0.76, and GC and gastritis with AUC of 0.64.
Accuracy  of  the  identified  45-autoantibody  signature  (0.745)  is  nearly  equal  to  the 
accuracy (0.74) of serum pepsinogen test (SPT)  that have a sensitivity 77% and specificity 
73% (at pepsinogen I level ≤ 70 ng/ml and pepsinogen I/II ≤ 3) and is widely used in Japan 
(63). Known disadvantage of SPT is a strong correlation with intestinal-type cancer only. We 
found that the serum score did not correlate with the histological type. It could be of interest 
to correlate the results of SPT test and autoantibody profiling as the combination of these 
approaches can open new possibilities for improving diagnostic accuracy.
Evidences on other known gastric cancer biomarkers show for CEA, CA19-9, CA50, 
CA72-4  highest  diagnostic  accuracy  0.53,  0.64,  0.59  and  0.75  respectively  (64-68,72). 
However, all this antigens shared between different types of cancer showing higher frequency 
in other, such as pancreatic or colorectal, cancers (69).
Although this study gave some insight into the pathological processes associated with 
the cancer-associated autoantibody production, generally their biological significance and the 
role  in  the  cancer  development  and  anti-tumour  immune  response  is  unknown.  A large 
number of wild-type self antigens analysed in this study were shown to elicit autoantibody 
production at similar frequencies in cancer patients and cancer-free healthy individuals. In the 
context of cancer immunoediting concept proposed by Robert Schreiber (37), it  would be 
tempting to speculate that these antibodies reflect the immune response during the elimination 
phase  of  nascent  tumour.  However,  detailed  molecular  examination  of  these  antigens 
performed by Dr. Siliņa (PhD thesis), failed to reveal somatic mutations or cancer-associated 
expression pattern of these antigens thus making it less likely that these antigens may have 
served as targets for the protective immune response. Conversely, we and others have rarely 
observed  the  autoantibody  production  against  tumour  associated  antigens,  such  as  CT 
antigens, in cancer-free controls (104,133). Immunogenicity of CT antigens is thought to be 
related to their expression pattern: they are expressed in a wide range of cancers, but normally 
their  expression  is  restricted  to  immuno-privileged  tissues  such as  testis,  fetal  ovary  and 
placenta. Hence they become exposed to the immune system only when expressed by tumors, 
therefore the immune response against these antigens could serve as a very specific indicator 
of cancer. If the immunosurveillance of nascent tumours is a general phenomenon, it could be 
expected that the immune responses against tumour-associated antigens, such as CT antigens, 
could be detected at a relatively high frequency in individuals without clinically detectable 
tumour. Hence, at the first glance, our data seems to argue against the cancer immunoediting 
concept. However, it has been demonstrated that the CT antigen expression tends to correlate 
with an advanced stage of the disease and is higher in metastatic than primary tumors (130). 
Thus  it  could  be  possible  that  tumors  start  to  express  CT antigens  only  after  they  have 
undergone elimination and equilibrium stages and their  expression represents a feature of 
immunologically  sculpted/advanced  cancers.  Alternatively,  it  could  be  possible  that  the 
elimination and equilibrium phases of immunoediting process rely entirely on T and/or NK 
cells and that B cells and/or autoantibody production are not involved in these processes and 
triggering  B cell  response  requires  a  specific  signal  (e.g.  sufficiently  large  tumour  mass, 
necrosis  of tumour cells  etc.)  absent at  the early phases of tumour development.  Another 
possibility  is  that  B  cells  may  promote  the  cancer  development.  In  fact,  it  has  been 
demonstrated that B cells have a key role in the initiation of tumor-promoting inflammation 
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(134), and that B cells repress antitumour immunity in TNF--dependent manner (135), hence 
it could be possible that the appearance of tumor-specific antibodies marks the point-of-no-
return in the cancer development/immunoediting process. In line with this, Willimsky G et al 
(136) has demonstrated that the initiation of B cell response to a tumor antigen coincides with 
the development of tumor-specific tolerance and cytotoxic T cell unresponsiveness.
Hence, it would be of great theoretical interest and clinical relevance to explore further 
the autoantibody profiles in various cohorts of patients, including the samples collected before 
the clinical diagnosis, as well as in patients undergoing immunotherapy, and to correlate the 
data with the prognostic information and the response to immunotherapy.
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 5. CONCLUSIONS
 The technology for production and processing of phage-displayed antigen microarrays 
was elaborated and it showed similar sensitivity to the phage plaque assay.
 The intra-assay variability of the phage-displayed antigen microarray technology was 
7%, while the average CV was ~13% in the inter-assay comparisons, which is 
generally acceptable variability for immunoassays.
 The application of phage-displayed antigen microarray technology for the 
characterization of the humoral immune response against sperm associated antigens 
revealed cancer-associated spontaneous humoral immune response against SPAG1, 
SPAG6, SPAG8 and a novel testis-restricted splice variant SPAG17-A1 that allowed to 
classify them as novel CT antigens with potential relevance as immunotherapeutic 
targets and serological biomarkers.
 Support vector machine using the improved kernel generated the biomarker model 
with higher classification accuracy for discriminating sera from cancer patients and 
healthy controls. However, the detailed examination of the biomarker model showed 
that it is based on the detection of small but consistent differences in the signal 
intensities between the cases and controls.
 The conventional methods for the normalization and statistical analysis commonly 
applied for DNA microarray data analysis are not suitable for the analysis of 
autoantibody profiles.
 The procedures for two-step normalization of microarray data, defining cutoffs and 
ranking of antigens were elaborated and allowed to discriminate between sero-positive 
and sero-negative cases and to perform quantitative analysis.
 Application of the phage-displayed antigen microarray technology and the developed 
data analysis approach for the exploration of autoantibody profiles in patients with 
gastric cancer gastric, inflammatory diseases and healthy individuals resulted in the 
identification of 45- autoantibody signature that could discriminate between GC and 
healthy control sera with 74.5% accuracy (AUC of 0.79, 58% sensitivity and 91% 
specificity), GC and peptic ulcer with 73.0% accuracy, and GC and gastritis with 
63.5% accuracy.
 The identified 45-autoantibody signature could detect stage I GC with equal sensitivity 
than advanced GC thus demonstrating its relevance for the early detection of GC. 
 At least in GC, the autoantibody production does not correlate with histological type, 
H. pylori status, grade, localization and size of the primary tumor while it appears to 
be associated with the metastatic disease.
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MAIN THESIS OF DEFENSE
I. The phage-displayed antigen microarray technology is a valuable tool for the 
exploration of autoantibody profiles in human sera and it has a potential to revel 
autoantibody signatures with the diagnostic relevance.
II. The microarray data analysis approach that allows to discriminate between sero-
positive and sero-negative cases and to perform quantitative analysis is of paramount 
importance for the analysis of autoantibody profiles.
III. The identified 45-autoantibody signature has higher specificity than currently known 
gastric cancer serum biomarkers and is applicable for the early detection of gastric 
cancer. 
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